

Binding of synGAP to PDZ Domains of PSD-95 is Regulated by Phosphorylation and Shapes the
Composition of the Postsynaptic Density

**Ward G. Walkup^{4th}¹, Tara Mastro¹, Leslie T. Schenker¹, Jost Vielmetter², Rebecca Hu¹,
Ariella Iancu¹, Meera Reghunathan¹, B. Dylan Bannon¹, and Mary B. Kennedy¹**

From ¹the Division of Biology and Biological Engineering and ²the Beckman Institute Protein
Expression Center, California Institute of Technology, Pasadena, CA 91125

To whom correspondence should be addressed: Mary B. Kennedy, Division of Biology and Biological
Engineering 216-76, California Institute of Technology, Pasadena, CA, USA 91125

Tel.: (626) 395-3924; Email: kennedym@its.caltech.edu

1 **ABSTRACT:**

2 SynGAP is a Ras/Rap GTPase-activating protein (GAP) present in high concentration in postsynaptic
3 densities (PSDs) from mammalian forebrain where it binds to all three PDZ (PSD-95, Discs-large, ZO-1)
4 domains of PSD-95. We show that phosphorylation of synGAP by Ca²⁺/calmodulin-dependent protein
5 kinase II (CaMKII) decreases its affinity for the PDZ domains as much as 10-fold, measured by surface
6 plasmon resonance. SynGAP is abundant enough in postsynaptic densities (PSDs) to occupy about one
7 third of the PDZ domains of PSD-95. Therefore, we hypothesize that phosphorylation by CaMKII reduces
8 synGAP's ability to restrict binding of other proteins to the PDZ domains of PSD-95. We support this
9 hypothesis by showing that three critical postsynaptic signaling proteins that bind to the PDZ domains of
10 PSD-95 are present at a higher ratio to PSD-95 in PSDs isolated from synGAP heterozygous mice.

11 **Introduction**

12 The postsynaptic density (PSD) is an organized complex of signaling proteins attached to the
13 postsynaptic membrane of excitatory glutamatergic synapses in the central nervous system. It comprises a
14 network of scaffold proteins, the most prominent of which is PSD-95, a member of the MAGUK family
15 (Membrane-Associated GUanylate Kinase-like proteins) (Kennedy, 2000). PSD-95 contains three PDZ
16 domains that bind transmembrane receptors and cytosolic signaling proteins by attaching to four to seven
17 residue sequences usually located at the C-terminus of the binding protein (Fig. 1A; Kornau et al., 1995;
18 Kornau et al., 1997). PSD-95 associates with itself and other scaffold proteins via its guanylate kinase-
19 like domain to form an interconnected network that spatially organizes receptors and biochemical signal
20 transduction machinery at the postsynaptic site (Baron et al., 2006; Sheng and Kim, 2011).

21 Formation and modulation of excitatory synapses involves *de novo* assembly and/or re-arrangement of
22 the proteins bound to PDZ domains of PSD-95 and other binding sites on the PSD scaffold (El-Husseini et
23 al., 2000; Steiner et al., 2008; Sturgill et al., 2009). One class of glutamate receptor channels, NMDA-type
24 glutamate receptors (NMDARs) bind directly to PDZ domains of PSD-95 via their cytosolic C-termini
25 (Kornau et al., 1995). A second class, AMPARs, bind indirectly to PDZ domains of PSD-95 through two

26 families of auxiliary subunits, TARPs (Transmembrane AMPA Receptor Regulatory Proteins) (Tomita et
27 al., 2005) and LRRTMs (Leucine-Rich Repeat TransMembrane proteins) (de Wit et al., 2009). AMPARs,
28 NMDARs, TARPs, and LRRTMs, along with the synaptic organizing molecule neuroligin, comprise the
29 most highly enriched transmembrane proteins precipitated together with PSD-95 from the postsynaptic
30 density fraction of mouse forebrain (Dosemeci et al., 2007). LRRTMs and neuroligin bind to presynaptic
31 neurexin, which promotes formation of new presynaptic vesicle release sites (Siddiqui et al., 2010).

32 A smaller number of cytosolic signaling proteins also associate directly with PDZ domains of PSD-95
33 (Brenman et al., 1996; Chen et al., 1998; Kim et al., 1998; Murphy et al., 2006; Sakagami et al., 2008).
34 Among these, the synaptic Ras/Rap GTPase activating protein synGAP is particularly interesting for
35 several reasons. It is unusually abundant in the PSD fraction; indeed, it is nearly as abundant in PSD-95
36 complexes as PSD-95 itself (Chen et al., 1998; Cheng et al., 2006; Dosemeci et al., 2007). The *synGAP*
37 gene displays a highly penetrant gene-dosage effect. Heterozygous deletion of *synGAP* in mice or
38 humans produces a pronounced cognitive deficit (Komiyama et al., 2002; Hamdan et al., 2009; Hamdan
39 et al., 2011; Berryer et al., 2013). This means that the amount of the *synGAP* protein is rate-limiting for at
40 least one critical process at the synapse. Finally, the carboxyl tails of two prominent *synGAP* splice
41 variants bind to all three of the PDZ domains of PSD-95 in yeast two hybrid assays (Kim et al., 1998). In
42 contrast, most other PSD-95 binding proteins bind specifically either to PDZ domains 1 and 2, or to PDZ3
43 (e.g. Kornau et al., 1995; Irie et al., 1997). Taken together, these characteristics suggest that *synGAP*
44 occupies a particularly large proportion of the PDZ domains of PSD-95 in most excitatory synapses;
45 therefore, a 50% reduction in the amount of *synGAP* available to bind to PSD-95 might have pathological
46 consequences for synaptic function.

47 Mutations in a single copy of *synGAP* have been causally implicated in ~ 9% of cases of non-
48 syndromic cognitive impairment associated with either autism (ASD) or epilepsy (Berryer et al., 2013).
49 Studies of the effects of such mutations in mice suggest a possible underlying neural mechanism.
50 Deletion of *synGAP* in cultured hippocampal neurons results in precocious formation of excitatory

51 synapses. Enlarged postsynaptic spines containing clusters of PSD-95 develop in mutant neurons two
52 days before they develop in wild-type neurons; and the precocious synapses contain a larger number of
53 AMPARs (Vazquez et al., 2004). Early maturation of synapses in mice with a heterozygous deletion of
54 synGAP shortens the critical period for experience-dependent synaptic development in the cortex
55 (Clement et al., 2013). A corresponding shortening of the critical period in humans may underlie
56 malformation of circuits with resulting cognitive impairment, autism, and/or epilepsy.

57 In mutant mouse neurons with a homozygous synGAP deletion, viral expression of recombinant wild-
58 type synGAP reverses the precocious synapse formation (Vazquez et al., 2004). Spine heads enlarge and
59 PSD-95 clusters enter synaptic spines at the normal time. In contrast, expression of synGAP lacking the
60 five-residue C-terminal PDZ domain ligand (Δ SXV) does not reverse the phenotype. Indeed, we observed
61 that, after expression of Δ SXV, the sizes of clusters of PSD-95 are larger than in the deletion mutant itself
62 and continue to enter the spine earlier than in wild-type neurons. SynGAP bearing the Δ SXV mutation
63 localizes normally to spines indicating that failure to rescue the phenotype is not caused by abnormal
64 localization. This observation led us to hypothesize that binding of synGAP to the PDZ domains of PSD-
65 95 might normally restrict the binding of other proteins that influence clustering of PSD-95 and its
66 movement into the spine. Recent work suggests that those proteins could include neuroligins (Sudhof,
67 2008), LRRTMs (Siddiqui et al., 2010) or TARPs (Tomita et al., 2005).

68 Phosphorylation of synGAP by CaMKII has recently been shown to induce movement of synGAP out
69 of the PSD in living neurons (Yang et al., 2013; Araki et al., 2015). In our recent study of
70 phosphorylation sites for CaMKII on r-synGAP, a soluble recombinant form of synGAP missing the first
71 100 N-terminal residues, we found one site (S1283) located very near the C-terminal PDZ domain ligand
72 (Fig. 1A; Walkup IV et al., 2015). Therefore, we tested whether phosphorylation of this site or others by
73 CaMKII reduces the affinity of synGAP for PDZ domains of PSD-95. Here we demonstrate that
74 phosphorylation of several sites in the disordered domain of synGAP and of S1283 dramatically reduces
75 binding of synGAP to all of the PDZ domains on PSD-95. We also report the unexpected finding that the

76 disordered domain of synGAP binds $\text{Ca}^{2+}/\text{CaM}$ with high affinity and this binding causes a smaller
77 reduction of affinity of synGAP for PDZ3. We hypothesize that phosphorylation of synGAP in the PSD,
78 triggered by activation of NMDARs, could substantially reduce the ability of synGAP to compete with
79 other proteins for binding to the PDZ domains of PSD-95, permitting increased equilibrium binding of
80 neuroligin, TARPs and/or LRRTMs. We support the hypothesis that binding of synGAP to PSD-95
81 restricts binding of other proteins by showing that the number of TARPs, LRRTM2, and neuroligin-2
82 molecules per molecule of PSD-95 is significantly increased in PSD fractions isolated from mice with a
83 heterozygous deletion of synGAP compared to those isolated from wild type mice.

84 We propose that reconfiguration of the PSD triggered by phosphorylation of synGAP and the
85 resulting decrease in its affinity for PDZ domains of PSD-95 facilitates formation of new synapses and/or
86 leads to strengthening of existing synapses in part by allowing increased trapping of AMPARs in the PSD
87 during the early stages of induction of long-term potentiation (LTP; Opazo and Choquet, 2011). This
88 proposed mechanism is consistent with the “slot” hypothesis for addition of new AMPA-receptors during
89 induction of LTP (Shi et al., 2001; Henley and Wilkinson, 2016), and we discuss how it can account for
90 many previous experimental observations.

91 **Results**

92 *Phosphorylation of R-synGAP by CaMKII Reduces Its Binding to PDZ Domains of PSD-95*– SynGAP
93 can be expressed in bacteria and purified in a soluble form by deleting the first 102 residues of its N-
94 terminus (Walkup IV et al., 2015). This version of synGAP, termed r-synGAP, retains all of the
95 identified functional domains, the “disordered” regulatory domain, and the C-terminal PDZ ligand (Fig.
96 1A). In a previous study we showed that r-synGAP is phosphorylated by CaMKII at several residues
97 including S1283, which is 7 residues upstream of the PDZ domain ligand located at residues 1290-1293
98 (Walkup IV et al., 2015). Because this phosphorylation site is so near the PDZ ligand, we wondered
99 whether its phosphorylation, or phosphorylation of other sites by CaMKII, would interfere with binding
100 of synGAP to PDZ domains of PSD-95. To test this, we incubated r-synGAP with affinity resins

101 substituted with recombinant PDZ domains as described under Materials and Methods. The beads
102 contained PDZ1 (61-151), PDZ2 (155-249), PDZ3 (302-402), a fragment containing PDZ1 and PDZ2
103 (PDZ12, 61-249), or a fragment containing all three PDZ domains (PDZ123, 61-402). Binding of r-
104 synGAP to the beads was tested with or without a prior 10 min phosphorylation by CaMKII. As expected,
105 without phosphorylation, r-synGAP binds specifically to each of the three PDZ domains (Fig. 1B). In this
106 assay, its binding is highest to PDZ3. Binding of r-synGAP to PDZ123 reveals a substantial avidity
107 effect; that is, the amount bound per individual PDZ domain is twice that bound to PDZ3 alone and four
108 times that bound to either PDZ1 or PDZ2 alone.

109 Phosphorylation by CaMKII reduces binding of synGAP to all of the individual PDZ domains and to
110 to the constructions comprising PDZ12 and PDZ123 (Fig. 1B). The reduction in binding requires the
111 presence of both Ca^{2+} /CaM and CaMKII in the phosphorylation reaction mixture (Fig. 1C). The fourth bar
112 of Fig. 1C shows that the reduction in binding is not caused by phosphorylation of PDZ domains on the
113 column by residual CaMKII. We have shown previously that as many as 10 sites on synGAP are
114 phosphorylated by CaMKII (Walkup IV et al., 2015). Approximately 5 of these, including site S1123, are
115 fully phosphorylated after a 0.5 min reaction (Walkup IV et al., 2015 and Fig. 1D). To test whether the
116 reduction in binding depends primarily on phosphorylation of the rapidly phosphorylated sites or requires
117 phosphorylation of most of the sites, we tested binding of r-synGAP to PDZ123 after phosphorylation for
118 various times (Fig. 1E). The reduction in binding is maximal after 0.5 min, indicating that
119 phosphorylation of the more rapidly phosphorylated sites is sufficient for full reduction of affinity.

120 *Affinity of R-synGAP for the PDZ Domains of PSD-95 Determined by Surface Plasmon Resonance*
121 (SPR)– The three PDZ domains of PSD-95 are located in the N-terminal half of the protein from residues
122 61 to 402. The first two PDZ domains are separated by 4 residues and the third is 53 residues downstream
123 of PDZ2. We determined the affinities of r-synGAP for individual PDZ domains, for PDZ12 and for
124 PDZ123 by a "competition in solution" assay in which SPR is used to detect the amount of free r-synGAP
125 in solutions containing a constant amount of r-synGAP and varying amounts of recombinant PDZ

126 domains (Nieba et al., 1996; Lazar et al., 2006; Abdiche et al., 2008). To detect the free synGAP,
127 recombinant PDZ domains are immobilized on the Biacore chip as described under Materials and
128 Methods. We used the competition method rather than conventional Biacore measurements in which
129 varying concentrations of r-synGAP are applied to a chip containing immobilized PDZ domains because
130 concentrations of r-synGAP above ~100 nM produced a large bulk resonance signal caused by high
131 viscosity that obscured the change in resonance produced by its binding to PDZ domains. The
132 competition assay eliminates the need to apply high concentrations of synGAP to the chip.

133 We generated a standard curve in which the maximum resonance responses of a series of
134 concentrations of synGAP from 0 nM to 50 nM (Fig. 2A, grey traces) were determined and plotted
135 against synGAP concentration (Fig. 2B, large grey dots). The data were fit with a hyperbolic curve. The
136 maximum resonance response of a series of mixtures containing 25 nM r-synGAP and increasing
137 concentrations of PDZ1 from 0 nM to 10 μ M were measured, and the concentration of r-synGAP
138 remaining free to bind to PDZ1 on the chip was then determined from the standard curve (Fig. 2B, small
139 black dots). A K_D of 140 ± 30 nM (Table 1) was calculated as described under Materials and Methods
140 (Fig. 2C). We used the same method to measure K_D s for PDZ2 and PDZ3 (Fig. 3A and B, respectively)
141 and K_{Dapp} s for PDZ12 and PDZ123 (Fig. 3C and D, respectively). The values are summarized in Table 1.
142 We obtained an additional value of 730 ± 50 nM for the K_D of PDZ3 by a conventional Biacore assay,
143 which is in good agreement with the K_D measured by the competition assay. These data show that, under
144 these conditions, PDZ1 has a higher affinity for synGAP than does PDZ3.

145 *Binding of R-SynGAP Phosphosite Mutants to PDZ123 Affinity Resin*– To determine which phos-
146 phorylation sites are important for the reduction in binding to PDZ domains that we observed in Fig. 1A,
147 we first examined binding of recombinant mutants of synGAP to PDZ123 affinity resin. Neither mutation
148 of site S1123 to alanine or aspartate nor double mutation of sites S1093 and S1123 to alanine alters
149 binding of r-synGAP to PDZ123 before phosphorylation (Fig. 4A). However, each of these mutations
150 reduces the effect of phosphorylation on binding compared to wild-type after 0.5 min of phosphorylation

151 by CaMKII. Mutation of S1123 to alanine had the same effect as double mutation of S1093 and S1123 to
152 alanines ($p = 0.6$), indicating that phosphorylation of S1093 has relatively little effect on binding to PDZ
153 domains; whereas, phosphorylation of S1123 contributes to the reduction of binding to PDZ domains, but
154 is not sufficient to produce the maximum reduction of binding. In contrast to S1123, mutation of S1283
155 alone to aspartate reduces the binding of r-synGAP to PDZ123 by ~50% relative to wild-type before
156 phosphorylation (Fig. 4B), suggesting that phosphorylation of this site alone causes substantial loss of
157 affinity for PDZ domains. Notably, none of the mutations interfere with the effect of ten min of
158 phosphorylation (Fig. 4A and B). Taken together, these results mean that phosphorylation of S1283 alone
159 significantly reduces binding of synGAP to PDZ domains, however maximum loss of binding can be
160 accomplished only by cumulative phosphorylation over ten min of several sites within the regulatory
161 disordered domain (See Fig. 1C in Ref. Walkup IV et al., 2015).

162 *Effect of Phosphorylation on Affinity of R-synGAP for PDZ123 Measured by SPR*– We measured the
163 apparent dissociation constant (K_{Dapp}) for binding to PDZ123 of r-synGAP phosphorylated for 10 min by
164 CaMKII, and of the phosphomimetic mutant r-synGAP S1283D. Phosphorylation for 10 min by CaMKII
165 increases the K_{Dapp} of r-synGAP approximately ten-fold (Fig. 5A, Table 1); whereas mutation of S1283 to
166 aspartate increases the K_{Dapp} approximately four-fold (Fig. 5B, Table 1). Thus, cumulative
167 phosphorylation of several sites on r-synGAP can reduce affinity for PDZ domains by an order of
168 magnitude; whereas, addition of a negative charge at S1283 alone can reduce the affinity by a factor of
169 four.

170 *Ca²⁺/CaM Binds Directly to R-synGAP*– While studying phosphorylation of r-synGAP by CDK5
171 (Walkup IV et al., 2015), we found that the presence of Ca²⁺/CaM in reactions with either CDK5/p35 or
172 CDK5/p25 doubled the rate and stoichiometry of the phosphorylation (Fig. 6A and B). Inclusion of Ca²⁺
173 or CaM alone in the phosphorylation reactions did not alter the rates or stoichiometry.

174 We tested whether this effect resulted from binding of Ca²⁺/CaM to CDK5/p35 (e.g. He et al., 2008)
175 by comparing the rates of phosphorylation of histone H1, a well-known substrate of CDK5 in the

176 presence and absence of $\text{Ca}^{2+}/\text{CaM}$ (Fig. 6C and D). Phosphorylation of Histone H1 by either CDK5/p35
177 or CDK5/p25 was unaffected by $\text{Ca}^{2+}/\text{CaM}$. This result suggests that $\text{Ca}^{2+}/\text{CaM}$ binds directly to r-
178 synGAP, causing a substrate-directed enhancement of its phosphorylation.

179 To further verify that $\text{Ca}^{2+}/\text{CaM}$ binds directly to r-synGAP, we showed that r-synGAP binds to a
180 CaM-Sepharose affinity resin in a Ca^{2+} -dependent manner, as would be expected if it binds $\text{Ca}^{2+}/\text{CaM}$
181 specifically and with significant affinity (Fig. 6 -figure supplement 1). We found that the presence of
182 $\text{Ca}^{2+}/\text{CaM}$ alone in a Ras- or Rap-GAP assay has no effect on the GAP activity of synGAP (Fig. 6 -figure
183 supplement 2).

184 *Affinity of Binding of R-synGAP to $\text{Ca}^{2+}/\text{CaM}$* – We measured the affinity of binding of $\text{Ca}^{2+}/\text{CaM}$ to
185 r-synGAP by the conventional SPR method on the Biacore as described under Materials and Methods.
186 CaM was immobilized on a chip, and r-synGAP was applied to it at concentrations from 0 to 75 nM (Fig.
187 7A). Analysis of the equilibrium phase of association at each concentration (Fig. 7B) yielded a K_D of $9 \pm$
188 1 nM, indicative of high affinity binding.

189 To begin to define the location of the high affinity $\text{Ca}^{2+}/\text{CaM}$ binding site, we compared the affinities
190 for $\text{Ca}^{2+}/\text{CaM}$ of r-synGAP and a C-terminal truncated protein, sr-synGAP (residues 103-725; Fig. 1A) by
191 a bead-binding assay as described under Materials and Methods. We measured the amount of each protein
192 bound to a fixed amount of CaM-Sepharose after incubation with increasing concentrations (Fig. 7C and
193 D). Both r-synGAP (Fig. 7C) and sr-synGAP (Fig. 7D) showed saturable binding to the CaM-Sepharose
194 resin, and did not bind to control Sepharose beads lacking CaM (data not shown). The data were fit to
195 hyperbolic curves and the K_D 's for binding of r-synGAP and sr-synGAP to $\text{Ca}^{2+}/\text{CaM}$ were calculated to
196 be 31 ± 3 nM and 210 ± 30 nM, respectively. Thus, the high affinity site appears to be located in the
197 regulatory disordered region of r-synGAP, which is missing in sr-synGAP. The K_D 's determined by the
198 bead-binding assay (31 ± 3 nM) and Biacore equilibrium binding (9 ± 1 nM) are in the range of those
199 reported for calcineurin (PP2B) and CaMKII, 1-10 nM (Hubbard and Klee, 1987; Cohen and Klee, 1988)
200 and 40-80 nM (Miller and Kennedy, 1985; Meyer et al., 1992; Hudmon and Schulman, 2002),

201 respectively. We did not detect any binding when sr-synGAP was injected onto the CaM-substituted
202 Biacore chip at concentrations from 10-2500 nM. Thus, the relatively weak binding of sr-synGAP
203 observed in the bead-binding assay is not reproducible when measured on the Biacore chip. These data
204 indicate that Ca²⁺/CaM binds only weakly, if at all, to the N-terminal half of synGAP. A meta-analysis
205 algorithm for detecting potential CaM-binding domains (Mruk et al., 2014) predicts two Ca²⁺/CaM
206 binding sites in the C-terminal half of synGAP, one from residues 1000-1030 and another in the putative
207 coiled coil domain from residues 1229-1253. The SPR measurements do not allow us to confirm or to
208 rule out the presence of two high affinity sites of similar affinity.

209 *Effect of Ca²⁺/CaM on binding of R-synGAP to PDZ Domains of PSD-95*– We tested whether binding
210 of Ca²⁺/CaM alters the binding of r-synGAP to PDZ domains by comparing binding to each affinity resin
211 in the presence or absence of Ca²⁺/CaM (Fig. 8A). The presence of Ca²⁺/CaM during incubation with
212 resin significantly reduces binding of r-synGAP to PDZ3 and to PDZ123, but not to PDZ1 and/or PDZ2.
213 Thus, binding of Ca²⁺/CaM has a more specific, but weaker, effect on binding to the PDZ domains than
214 does phosphorylation. The effects of phosphorylation and of the presence of Ca²⁺/CaM during incubation
215 with resin are not additive (Fig. 8B); that is, the presence of Ca²⁺/CaM during the incubation with resin
216 does not further decrease binding of phosphorylated r-synGAP to PDZ123.

217 *SynGAP haploinsufficiency alters the composition of the PSD*– The physiological significance of the
218 finding that phosphorylation by CaMKII decreases the affinity of synGAP for the PDZ domains of PSD-
219 95 is best considered in the context of the high copy number of synGAP in the PSD. In molar terms,
220 synGAP is approximately as abundant in the PSD as PSD-95 itself (Chen et al., 1998; Cheng et al., 2006;
221 Dosemeci et al., 2007; Sheng and Hoogenraad, 2007). Because one synGAP molecule can bind to any one
222 of the three PDZ domains in each molecule of PSD-95, synGAP could occupy as many as one third of the
223 PDZ domains of PSD-95 in an average PSD. Our data suggest that phosphorylation of synGAP by
224 CaMKII, triggered by activation of NMDARs, would promote dissociation of synGAP from the PDZ
225 domains, reducing its ability to compete with other proteins for binding. We therefore propose that

226 synGAP normally functions to limit the number of available PDZ domains in the PSD-95 complex, and
227 that phosphorylation of synGAP by CaMKII partially alleviates the restriction, enabling reconfiguration
228 of the PSD scaffold. This proposed function is distinct from synGAP's role as a regulator of Ras and Rap
229 and could explain its unusually high abundance in the PSD which, until now, has been mysterious (Chen
230 et al., 1998; Sheng and Hoogenraad, 2007).

231 *SynGAP*^{+/-} mice have been shown to have about half as much synGAP in homogenates from forebrain
232 as *wild-type* litter mates. Because binding equilibria are driven not only by the intrinsic affinities of the
233 binding partners, but also by their concentrations, one prediction of our proposed hypothesis is that
234 synGAP haploinsufficiency, which reduces the amount of synGAP in the brain by 50% (Vazquez et al.,
235 2004), will cause a significant increase in binding to PSD-95 of other prominent PSD-95 binding proteins,
236 such as TARPs, LRRTM2s, or neuroligins. Thus, PSDs isolated from *SynGAP*^{+/-} mice would be predicted
237 to have less synGAP and more TARPs, LRRTMs, and/or neuroligins bound to PSD-95 than do PSDs
238 isolated from *wild-type* mice. We prepared PSD fractions from the forebrains of six *SynGAP*^{+/-} mice and
239 from six *wild-type* litter mates and measured the ratios of synGAP, TARPs, LRRTM2, neuroligin-1, and
240 neuroligin-2 to PSD-95 in the two fractions by quantitative immunoblot as described in Materials and
241 Methods (Fig 9). As predicted, the level of synGAP is decreased in relation to PSD-95 by ~ 25% in PSDs
242 ($p = 0.0007$) from the *SynGAP*^{+/-} mice (Fig. 9A). Furthermore, the ratios of TARPs 2,3,4,γ8, and of
243 LRRTM2 to PSD-95 are significantly increased (Fig. 9B,C; TARP/PSD-95, ~15%, $p = 0.017$;
244 LRRTM2/PSD-95, ~16%, $p = 0.0035$). This result means that, as predicted, the increase in availability of
245 PDZ1/2 domains on PSD-95 in the *SynGAP*^{+/-} mice enhances steady-state binding of TARPs and LRRTMs
246 to those sites. Interestingly, the ratio of neuroligin-1 to PSD-95 is unchanged in the *SynGAP*^{+/-} mice (Fig.
247 9D), suggesting that increased availability of PDZ3 on PSD-95 is not a strong driver of association of
248 neuroligin-1 with the PSD fraction. However, the ratio of neuroligin-2 to PSD-95 (Fig. 9E) is increased
249 ~10% ($p = 0.019$). Neuroligin-2 normally associates mostly with inhibitory synapses and mediates their
250 maturation (Varoqueaux et al., 2004). However, Levinson et al. (2005) reported that over-expression of

251 PSD-95 in neurons causes a redistribution of neuroligin-2, increasing the proportion associated with
252 excitatory synapses. Taken together, these results verify the prediction that a decrease in availability of
253 synGAP in the PSD scaffold, releases a restriction on binding of TARPs, LRRTMs, and neuroligin-2 to
254 PSD-95 *in vivo* and increases their association with the PSD.

255 **DISCUSSION**

256 We have shown that phosphorylation of specific sites on synGAP by CaMKII substantially reduces
257 the affinity of synGAP's PDZ ligand for all three of the PDZ domains of PSD-95, and we hypothesize
258 that this regulation helps to control the composition of the PSD at excitatory synapses. Recently, two
259 other groups found that movement of synGAP out of the PSD can be triggered in living neurons by
260 phosphorylation by CaMKII (Yang et al., 2013; Araki et al., 2015). In the Araki study, the authors
261 suggested that phosphorylation of synGAP results in "dispersion" of synGAP away from the PSD and
262 therefore would have the effect of upregulating Ras or Rap near the PSD. We propose here that a more
263 important consequence of the decrease in binding of synGAP to the PDZ domains of PSD-95 is
264 readjustment of the composition of the PSD resulting from increased availability of the PDZ domains of
265 PSD-95. A cartoon version of this proposed mechanism is shown in Fig. 10. An average PSD (~360 nm
266 in diameter) is estimated to contain ~300 molecules of PSD-95 with 900 PDZ domains (Chen et al., 2005;
267 Sugiyama et al., 2005). Because synGAP is nearly as abundant in PSD-95 complexes as PSD-95 itself
268 (Chen et al., 1998; Cheng et al., 2006; Dosemeci et al., 2007), synGAP could occupy as many as 300 PDZ
269 domains in an average synapse. Other proteins that compete for binding to PDZ1 and 2 of PSD-95 include
270 TARPs and LRRTMs. SynGAP may play an important role in limiting the size and strength of the
271 synapse by limiting and helping to regulate the available "slots" that can bind AMPAR complexes
272 (Hayashi et al., 2000; Shi et al., 2001; Opazo et al., 2012). Our hypothesis predicts that PSDs from mice
273 with a deletion of one copy of the synGAP gene will contain fewer copies of synGAP and more copies of
274 other proteins that bind to PSD-95. Indeed, we have shown here that PSD fractions from *synGAP*^{-/+} mice
275 have ~25% less synGAP per molecule of PSD-95 than those from *wild-type* mice; and, in contrast, they

276 have significantly more TARP proteins (~15%), LRRTM2 (~16%), and neuroligin-2 (~9%) per molecule
277 of PSD-95. The ratio of neuroligin-1 to PSD-95 is not altered.

278 Because binding between molecules is driven by both the inherent affinity between the binding
279 components and by their concentrations, a reduction in binding of synGAP to PDZ domains on PSD-95
280 produced by phosphorylation by CaMKII, rather than by haploinsufficiency, will also lead to an increase
281 in the amounts of TARP and LRRTM2, and/or neuroligin-2 in PSDs of *wild-type* animals. Acute
282 phosphorylation of synGAP by CaMKII following activation of NMDARs during induction of LTP could
283 initiate rearrangement of the composition of PSDs of individual synapses by causing an increase in
284 equilibrium binding of TARPs, LRRTMs, and their associated AMPARs in the PSD as they diffuse from
285 perisynaptic locations. Indeed, the dynamics of movements of synGAP and AMPARs visualized in living
286 neurons following synaptic stimulation are consistent with this hypothesis. Activation of NMDARs and
287 CaMKII causes dispersal of synGAP away from the PSD within a few minutes (Yang et al., 2013; Araki et
288 al., 2015). The same stimuli produce an equally rapid increase in the rate of trapping of AMPARs at
289 synaptic sites (Opazo et al., 2010; Opazo et al., 2012). Thus, the rates of these two processes observed in
290 living neurons are compatible with the notion that reduced binding of synGAP to PSD-95 during induction
291 of LTP opens up binding slots for AMPAR complexes.

292 Subsequent dephosphorylation of synGAP might be expected to allow synGAP to displace the newly
293 added TARPs and LRRTMs. Thus, additional processes occurring later in the consolidation of LTP would
294 be needed to stabilize the newly added AMPARs in the synapse. These could include degradation of the
295 phosphorylated synGAP and its replacement by newly synthesized alternatively-spliced isoforms that lack
296 the C-terminal PDZ binding domain (McMahon et al., 2012).

297 The restriction by synGAP of binding of neuroligins, in particular neuroligin-2, to PDZ3 of PSD-95
298 may be more significant during development, during formation of new synapses, or perhaps in later phases
299 of consolidation of LTP in adults. It is not clear whether a pool of perisynaptic neuroligins exists that could
300 be readily recruited to new synaptic sites over a few minutes after phosphorylation of synGAP. In any

301 case, the increased steady state amounts of TARPs, LRRTMs, and the small increase in neuroligin-2 that
302 we observe in excitatory PSDs isolated from forebrain would increase the overall excitatory/inhibitory
303 (E/I) balance of synapses onto neurons (Levinson and El-Husseini, 2005).

304 In addition to predicting the altered composition of the PSD in *synGAP^{r/+}* mice, our hypothesis
305 provides a mechanism to explain puzzling results from earlier studies. Neurons cultured from *synGAP*
306 deficient mice have been reported by several groups to have a higher average number of AMPARs at their
307 synapses than wild-type neurons (Kim et al., 2003; Vazquez et al., 2004; Rumbaugh et al., 2006). The two
308 PSD-95 binding proteins that are proportionally increased in *synGAP* heterozygotes, TARPs and
309 LRRTMs, bind subunits of AMPARs, and are believed to dock them in the synapse by binding to the PDZ
310 domain “slots” on PSD-95 (Tomita et al., 2005; de Wit et al., 2009). Our data indicates that the increase in
311 AMPARs in *synGAP^{+/-}* mice is a direct result of increased binding of TARPs and LRRTM to PDZ
312 domains that are made available by the reduced amount of *synGAP*.

313 A second example is the observation that absence of *synGAP* in hippocampal neurons cultured from
314 *synGAP* deficient mice leads to accelerated maturation of spines, including early movement of PSD-95
315 into spine heads, and ultimately larger clusters of PSD-95 in individual synapses compared to *wild-type*
316 neurons (Vazquez et al., 2004). We found that expression of *wild-type-synGAP* in the mutant neurons
317 rescued all of these phenotypes; however, expression of *synGAP* with a deletion of the five residue PDZ
318 ligand (*ΔSXV*) failed to rescue any of the effects of *synGAP* deficiency on accelerated maturation of
319 spines. In fact, expression of *synGAP-ΔSXV* actually further increased the size of clusters of PSD-95 in
320 spines compared to *wild-type* neurons. This failure to rescue the phenotypes was not a result of
321 mislocalization of *synGAP*; *synGAP-ΔSXV* localized normally to developing spine heads. Instead, the data
322 are consistent with the idea that *synGAP* normally competes with several proteins for binding to the PDZ
323 domains of PSD-95, and thus limits the size of clusters of PSD-95 and its associated proteins, as well as
324 their movement into spine heads (Vazquez et al., 2004).

325 We note that the reduction in affinity of synGAP for PDZ domains of PSD-95 after phosphorylation by
326 CaMKII is apparently not sufficient for complete dispersal of synGAP away from the PSD, although it is
327 likely necessary. We found that synGAP- ΔSXV , which cannot bind to PDZ domains, still localizes to
328 synaptic spines (Vazquez et al., 2004). Furthermore, Barnett et al. (Barnett et al., 2006) showed that, in
329 developing S1 rodent cortex, isoforms of synGAP that do not contain the PDZ ligand are, nevertheless,
330 bound to the PSD. These data mean that reduction of affinity of synGAP for PDZ domains may be
331 sufficient to decrease its ability to compete for binding slots on PSD-95; however, complete detachment of
332 synGAP from the PSD *in vivo* appears to require additional events.

333 Others have proposed that, in general, PDZ domains act as flexible protein interaction points that can
334 be modified to support changes in cytoplasmic organization (Kurakin et al., 2007). Complexes formed by
335 PDZ domain interactions are examples of linked equilibria, the stable configurations of which are
336 determined by the concentrations of each component and by their affinities for the relevant PDZ domains.
337 Evidence has indicated that PSD-95 protein complexes exist in dynamic equilibrium permitting continual
338 turnover and potential rearrangement of their composition (Sturgill et al., 2009; Schapitz et al., 2010).
339 SynGAP is an abundant protein in the PSD with a relatively high affinity for all three of the PDZ domains
340 of PSD-95; therefore, it will occupy a relatively large number of its PDZ domains at equilibrium. However,
341 when synGAP's affinities for the PDZ domains are reduced after phosphorylation, other components will
342 begin to compete more effectively for binding and the composition of the PSD-95 complex will shift to a
343 new equilibrium.

344 The functional significance of our finding that synGAP contains a high affinity binding site for
345 Ca^{2+} /CaM is less clear. We have shown that binding of Ca^{2+} /CaM alters the conformation of the carboxyl
346 terminal regulatory domain of synGAP allowing CDK5 to phosphorylate additional sites; the binding also
347 reduces the affinity of synGAP for PDZ3 by ~25%. However, the consequences of these two effects for
348 synaptic function are not known. However, once again, the high copy number of synGAP in the PSD may
349 provide a clue. The biochemical events initiated by Ca^{2+} flux through NMDARs that lead to changes in

350 synaptic strength (Sjostrom and Nelson, 2002) are initiated by formation of transient and limiting
351 concentrations of $\text{Ca}^{2+}/\text{CaM}$ in the spine (Markram et al., 1998; Pepke et al., 2010). Approximately ten
352 regulatory enzymes compete for binding of, and activation by, this $\text{Ca}^{2+}/\text{CaM}$ (Kennedy, 2013). Because of
353 the abundance of synGAP in the PSD, the high affinity binding site for $\text{Ca}^{2+}/\text{CaM}$ on synGAP will compete
354 effectively for the newly formed $\text{Ca}^{2+}/\text{CaM}$ and may act as a $\text{Ca}^{2+}/\text{CaM}$ buffer.

355 Haploinsufficiency of synGAP in humans is the cause of ~5% of cases of nonsyndromic cognitive
356 disability and ~9% of such cases with co-morbid Autism Spectrum Disorder or Epilepsy (Berryer et al.,
357 2013). The reduced amount of synGAP and resulting decrease in its ability to compete for PDZ domains
358 are almost certainly significant factors in the pathology of these disorders, perhaps more significant than
359 the reduction in synaptic Ras/Rap GAP activity. The increase in E/I balance in the forebrain predicted by
360 our results could produce the symptoms of cognitive disability, ASD, and/or epilepsy observed in humans
361 with synGAP haploinsufficiency. It would be worth considering whether pharmaceutical agents could be
362 designed that would bind to PDZ domains of PSD-95 and compensate for the reduced level of synGAP.

363 **Materials and Methods**

364 *Cloning, Expression and Purification of R-synGAP*– Soluble, recombinant synGAP (r-synGAP),
365 comprising residues 103-1293 in synGAP A1- α 1 (118-1308 in synGAP A2- α 1), or sr-synGAP,
366 comprising residues 103-725 in synGAP A1- α 1 (118-740 in synGAP A2- α 1), was purified from *E. coli* as
367 previously described (Walkup IV et al., 2015). The isoform names and residue numbering are taken from
368 ref. (Walkup IV et al., 2015). Henceforth, except where indicated, we use residue numbering
369 corresponding to synGAP A1- α 1.

370 Briefly, a pET-47b(+) plasmid (EMD Millipore, Billerica, MA, catalog no. 71461) containing
371 synGAP cDNA (AF048976) fused to an N-terminal 6x Histidine Tag and a PreScission Protease cleavage
372 site was transformed into the Rosetta2(DE3) *E. coli* strain (EMD Millipore, catalog no. 71397) for protein
373 expression. Bacterial pellets were harvested by centrifugation and lysed by microfluidization in a ML-110
374 microfluidizer (Microfluidics Corp., Westwood, MA). Soluble synGAP was purified on Talon Metal

375 Affinity Resin (Clontech, Mountain View, CA, catalog no. 635503), and concentrated by ultrafiltration
376 through a 150 kDa cutoff-filter (Thermo Scientific, Waltham, MA, catalog no. 89923) for r-synGAP or 9
377 kDa cutoff-filter (Thermo Scientific, catalog no. 89885A) for sr-synGAP. Concentrated samples of r-
378 synGAP were exchanged into storage buffer (20 mM Tris, pH 7.0; 500 mM NaCl, 10 mM TCEP, 5 mM
379 MgCl₂, 1 mM PMSF, 0.2% Tergitol Type NP-40, and Complete EDTA-free protease inhibitor) by
380 ultrafiltration, flash-frozen in liquid nitrogen, and stored at -80° C. Sr-synGAP was further purified on a
381 size exclusion column prior to storage (Walkup IV et al., 2015).

382 *Cloning, Expression and Purification of PDZ Domains from PSD-95*– Soluble recombinant PDZ
383 domains, comprising residues 61-151 (PDZ1), 155-249 (PDZ2), 302-402 (PDZ3), 61-249 (PDZ12), and
384 61-403 (PDZ123) from murine PSD-95 (Q62108) were purified from *E. coli* as previously described
385 (Walkup IV and Kennedy, 2014, 2015) with the modifications below.

386 Briefly, pJExpress414 plasmids (DNA2.0, Menlo Park, CA, catalog no. pJ414) containing codon
387 optimized PDZ domains were transformed into the BL21(DE3) *E. coli* strain (EMD Millipore, catalog no.
388 70235-3) for protein expression. Single colonies of BL21(DE3) cells harboring pJExpress414 plasmids
389 were grown overnight at 37 °C in lysogeny broth (LB) (Teknova, Hollister, CA, catalog no. L9110)
390 supplemented with 100 µg/ml carbenicillin. Overnight cultures were diluted 1:500 into LB medium and
391 grown at 37 °C until cultures reached an O.D.₆₀₀ of 1.0. IPTG was added to a final concentration of 0.2
392 mM, and cultures were grown for an additional 4.5 hours at 37 °C. Bacterial pellets were harvested by
393 centrifugation and lysed using non-ionic detergent (BugBuster) and ReadyLyse. Soluble PDZ1, PDZ2
394 and PDZ12 domains were purified on GluN2B peptide (GAGSSIESDV) PDZ Ligand Affinity Resin
395 (Walkup IV and Kennedy, 2014) by eluting with 400 µg/ml SIETEV peptide. PDZ3 and PDZ123 were
396 purified on CRIPT peptide (GAGNYKQTSV) PDZ Ligand Affinity Resin (Walkup IV and Kennedy,
397 2014) by eluting with 400 µg/ml YKQTSV peptide. PDZ domains were concentrated by ultrafiltration
398 through a 3 kDa Amicon Ultracentrifugal Filter Unit (EMD Millipore, catalog no. UFC 900396). The
399 PDZ peptide ligands were removed from PDZ domains by dialysis into storage buffer (50 mM HEPES,

400 pH 7.5; 100 mM NaCl, 5 mM TCEP, 1 mM PMSF, and Complete EDTA-free protease inhibitor).
401 Purified PDZ domains (>99% pure; 45-610 μ M; Fig. 1 figure supplement 1) were flash-frozen in liquid
402 nitrogen, and stored at -80° C.

403 *SDS-PAGE, Immunoblotting and Assessment of Protein Purity and Yield*– We used SDS-PAGE to
404 determine purity of proteins and to quantify binding to PDZ domain resin. Protein samples were diluted
405 1:3 into 3x Laemmli buffer (100 mM Tris HCl, pH 6.8; 2.1% SDS, 26% glycerol, 7.5% β -
406 mercaptoethanol, and 0.01% bromophenol blue) and heated to 95° C for 3 minutes before fractionation on
407 8% SDS-PAGE gels at 165 V in 25 mM Tris base, 192 mM glycine, 0.1% SDS. Proteins were stained
408 with Gel Code Blue (Thermo Scientific, catalog no. 24592), imaged on a LI-COR Odyssey Classic
409 Infrared Imaging System (LI-COR Biosciences, Lincoln, NE) at 700 nm, and quantified with LI-COR
410 Image Studio Software (v4.0.21) against standard curves of BSA (catalog no. A7517-1VL) and lysozyme
411 (catalog no. L4631-1VL) purchased from Sigma-Aldrich, St. Louis, MO. The protein standards were
412 loaded onto each gel in lanes adjacent to the protein samples. Molecular weights of stained proteins were
413 verified by comparison to Precision Plus Protein All Blue Standards (BioRad, Hercules, CA, catalog no.
414 161-0373).

415 For immunoblotting, proteins fractionated by SDS-PAGE were electrically transferred to low
416 fluorescence PVDF membranes (Thermo Scientific, catalog no. 22860) in 25 mM Tris, 200 mM glycine,
417 and 20% methanol. Membranes were washed with 50 mM Tris-HCl, pH 7.6; 150 mM NaCl (TBS)
418 followed by blocking with Odyssey Blocking Buffer (LI-COR Biosciences, catalog no. 927-50000).
419 Membranes were washed in TBS supplemented with 0.1% Tween 20 (TBS-T) before incubation in
420 Odyssey Blocking Buffer containing 1:1000 diluted rabbit anti-synGAP (Pierce, Rockford, IL, catalog no.
421 PA1-046) or 1:1500 BSA-free anti-TetraHis (Qiagen, Germany, catalog no. 34670). Bound antibodies
422 were detected with 1:10,000 goat anti-mouse Alexa-Fluor 680 (Life Technologies, Carlsbad, CA, catalog
423 no. A-21057) or 1:10,000 goat anti-rabbit Alexa-Fluor 680 (Life Technologies, catalog no. A-21109)

424 visualized with a LI-COR Odyssey Classic Infrared Imaging System and quantified with LI-COR Image
425 Studio Software.

426 *Synthesis of PDZ Domain Affinity Resins*— PDZ domain affinity resins (PDZ1, residues 61-151;
427 PDZ2, residues 155-249; PDZ3, residues 302-402; PDZ12, residues 61-249; PDZ123, residues 61-402
428 from murine PSD-95) were prepared by the HaloTag-HaloLink method as previously described (Walkup
429 IV and Kennedy, 2014, 2015). Briefly, bacterial cell pellets containing PDZ domain-HaloTag fusion
430 proteins were resuspended in 10 ml/g of Purification Buffer, and lysed by three passes through a ML-110
431 microfluidizer. The lysate was clarified by centrifugation, added to HaloLink resin (Promega, Madison,
432 WI, catalog no. G1915), and mixed with continuous agitation for 1.5 hours at 4° C on an end-over-end
433 mixer. Unbound protein was separated from the resin by centrifugation and the PDZ-HaloTag-HaloLink
434 resin was resuspended, transferred to a column, and allowed to settle. The resin was extensively washed
435 and then stored at 4° C in a buffer supplemented with 0.05% NaN₃. The resin was used or discarded
436 within 1 week of preparation. The densities of PDZ domains on the resin varied from 50 to 100 pmol of
437 PDZ123 domain and from 200 to 500 pmol of PDZ1, PDZ2, PDZ3, or PDZ12 domains per µl resin.

438 *Assay for Binding of R-synGAP to PDZ domain Resin*— Phosphorylated or non-phosphorylated
439 synGAP (500 nM, 200 µl) was mixed with 20 µl of affinity resin containing PDZ1, PDZ2, PDZ3, PDZ12,
440 or PDZ123 domains, pre-equilibrated with Binding/Wash Buffer (25 mM Tris, pH 7.0; 150 mM NaCl, 1
441 mM MgCl₂, 0.5 mM TCEP, 0.2% Tergitol, 0.5 mM EDTA) in a cellulose acetate spin cup (Pierce, catalog
442 no. 69702) for 60 min on an end-over-end mixer. In some experiments, 2.5 µM CaM and 0.5 mM CaCl₂
443 were included to test the effect of binding of Ca²⁺/CaM to synGAP on synGAP's affinity for PDZ
444 domains. After the incubation, the resin in the spin cup was centrifuged for 2 min at 1,500 x g to remove
445 unbound protein, and the resin was washed 4 times with 200 µl of Binding/Wash Buffer. To elute bound
446 protein, 100 µl of 1x Laemmli Buffer was added and the resin was incubated for 5 min at room
447 temperature. The eluted protein was collected by centrifugation at 6,000 x g for 2 min, fractionated by
448 SDS-PAGE, stained with Gel Code Blue, and quantified on a LI-COR Classic as described above.

449 Integrated intensities reflecting the amount of bound synGAP were determined with LI-COR software
450 and plotted with Prism (v6.0d, GraphPad Software, La Jolla CA).

451 *Phosphorylation of R-synGAP by CaMKII for PDZ Binding Assays*– Phosphorylation of r-synGAP by
452 CaMKII was carried out immediately prior to PDZ binding assays, as previously described (Walkup IV et
453 al., 2015). Reaction mixtures contained 50 mM Tris-HCl, pH 8.0; 10 mM MgCl₂, 0 or 0.7 mM CaCl₂, 0.4
454 mM EGTA, 30 μM ATP, 0 or 3.38 μM CaM, 10 mM DTT, 725 nM r-synGAP, and 0 or 10 nM CaMKII.
455 Samples were quenched by addition of 1/3 volume of 50 mM Tris, pH 8.0; 0.4 M NaCl, 10 mM MgCl₂,
456 0.8% tergitol (Type NP-40), 6 μM autocamtide-2 related inhibitory peptide (Genscript, China), 40 mM
457 EGTA at the indicated times. When we planned to add Ca²⁺/CaM during the subsequent incubation with
458 resin, the EGTA was omitted. Samples were stored on ice until their use in PDZ domain binding assays.

459 *Stoichiometry and Rate of Phosphorylation of R-synGAP and Histone H1 by CaMKII and/or CDK5*–
460 Phosphorylation of 725 nM synGAP by 10 nM CaMKII was carried out as previously described (Walkup
461 IV et al., 2015) in reaction mixtures containing 50 mM Tris-HCl, pH 8.0, 10 mM MgCl₂, 0 or 0.7 mM
462 CaCl₂, 0.4 mM EGTA, 500 μM [γ -³²P]-ATP (375 cpm/pmol) (6000 Ci/mmol, Perkin Elmer, Waltham,
463 MA, catalog no. BLU002Z/NEG002Z), 0 or 3.4 μM CaM, 10 mM DTT. Phosphorylation of 286 nM r-
464 synGAP and 4.3 μM Histone H1 (New England Biolabs, Ipswich, MA, catalog no. M2501S), by
465 CDK5/p35 (EMD Millipore, catalog no. 14-477M) or CDK5/p25 (EMD Millipore, catalog no. 14-516)
466 was carried out in the same reaction mixture containing 110 nM CDK5/p35 or CDK5/p25 but no
467 CaMKII. After fractionation by SDS-PAGE, phosphorylated proteins were quantified with a Typhoon LA
468 9000 phosphorimager (GE Healthcare Life Sciences, Pittsburg, PA) as previously described (Walkup IV
469 et al., 2015). Relative densities were converted to pmol phosphate by comparison to densities of standard
470 amounts of [γ -³²P]-ATP. The stoichiometry of phosphorylation was calculated by dividing mol of
471 incorporated phosphate by mol of synGAP loaded per lane.

472 *Measurement of Affinity of R-synGAP for PDZ Domains by Surface Plasmon Resonance (SPR)*– We
473 used a “competition in solution” method (also called “affinity in solution”) (Nieba et al., 1996; Lazar et

474 al., 2006; Abdiche et al., 2008) to measure the affinity of r-synGAP for PDZ domains. In this method,
475 PDZ domains are immobilized on the chip surface and used to capture and measure the concentration of
476 free r-synGAP in pre-equilibrated mixtures of a constant amount of r-synGAP with varying amounts of
477 soluble recombinant PDZ domains. Experiments were performed on a Biacore T200 (GE Healthcare Life
478 Sciences). Purified PDZ domains (PDZ1, PDZ2, PDZ3, PDZ12, PDZ123 from PSD-95) were coupled to
479 Series S CM5 Sensor Chips (GE Healthcare Life Sciences, catalog no. BR-1005-30) by the amine
480 coupling protocol specified in the Biacore T200 Control Software with reagents purchased from GE
481 Healthcare Life Sciences. Sensor surfaces were activated by applying a 1:1 mixture of 50 mM N-
482 hydroxysuccinimide (NHS) : 200 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride
483 (EDC) provided in the Biacore Amine Coupling Kit (GE Healthcare Life Sciences, catalog no. BR-1000-
484 50) dissolved in HBS-N running buffer (degassed 0.01 M HEPES pH 7.4, 0.15 M NaCl) (GE Healthcare
485 Life Sciences, catalog no. BR-1006-70). PDZ domains were diluted to 0.1-5 μ M in Biacore Sodium
486 Acetate Buffer [10 mM sodium acetate, pH 4.0 (GE Healthcare Life Sciences, catalog no. BR-1003-49)
487 for PDZ1 and PDZ3; pH 4.5 for PDZ2; pH 5 for PDZ12 and PDZ123]. PDZ domains were injected into
488 flow cells 2 and 4 until 200 to 400 RU (resonance units) of PDZ domain were immobilized. Flow cells 1
489 and 3 were left blank to be used as reference surfaces. Ethanolamine (1 M, pH 8.5) was injected for 7 min
490 at 10 μ l/min to block remaining active sites on all four flow cells.

491 A calibration curve was prepared by applying samples of 0 to 50 nM r-synGAP prepared by two-fold
492 serial dilution of 50 nM r-synGAP into 1x HBS-EP+ buffer (degassed 0.01 M HEPES, pH 7.4; 0.15 M
493 NaCl, 3 mM EDTA, 0.05% v/v Surfactant P20; GE Healthcare Life Sciences, catalog no. BR-1006-69) to
494 the chip and recording the maximum RU for each concentration. Samples for calibration were incubated
495 for 2 hours at room temperature before randomized injection onto the chip surface at 25° C at 10 μ l/min
496 for 200 sec over all four flow cells. Between each sample injection, the chip was regenerated by injecting
497 1 M MgCl₂ at 100 μ l/min for 60 sec, waiting 180 sec for the baseline to stabilize, then injecting a second
498 pulse of MgCl₂ solution, waiting 300 sec for the baseline to stabilize, and finally executing a “carry over
499 control injection” in which HBS-EP+ buffer is flowed over the chip surface at 40 μ l/min for 30 sec.

500 Mixtures of r-synGAP and PDZ domains were prepared by 1:1 dilution of 50 nM r-synGAP with two-
501 fold serial dilutions of PDZ domains (0-20 μ M PDZ1, PDZ2, PDZ3, PDZ12 or 0-160 μ M PDZ123) in
502 HBS-EP+ buffer to produce mixtures containing 25 nM r-synGAP and 0-10 μ M PDZ1, PDZ2, PDZ3,
503 PDZ12 or 0-80 μ M PDZ123. For each mixture of r-synGAP and PDZ domain, the different
504 concentrations were injected randomly and a series of sensorgrams were recorded as described for the
505 calibration curve.

506 Sensorgrams were processed with Biacore T200 Evaluation Software, (ver. 3.0, GE Healthcare Life
507 Sciences). The y-axes were zeroed at the baseline for each cycle and x-axes were aligned at the injection
508 start. Bulk refractive index changes and systematic deviations in sensorgrams were removed by
509 subtracting the responses in reference flow cells corresponding to the sample flow cells (e.g. 2-1, 4-3).
510 The averaged sensorgrams for 0 nM r-synGAP were then subtracted from sensorgrams for all other
511 concentrations. The concentrations of free r-synGAP in each mixture with PDZ domains was determined
512 from the calibration curve, exported into Prism, and plotted against the log of PDZ domain concentration.
513 The curve was fit to the equation:

$$514 \quad \text{synGAP}_{\text{free}} = \frac{(\text{synGAP}_{\text{tot}} - \text{PDZ}_{\text{tot}} - K_D)}{2} \pm \sqrt{\frac{(\text{PDZ}_{\text{tot}} + \text{synGAP}_{\text{tot}} + K_D)^2}{4} - (\text{PDZ}_{\text{tot}} \times \text{synGAP}_{\text{tot}})}$$

515 Equilibrium dissociation constants (K_D) for binding to PDZ1, PDZ2, and PDZ3, and apparent
516 equilibrium dissociation constants for binding to PDZ12 and PDZ123 ($K_{D\text{app}}$) were determined from the
517 best fit curves as described in the Biacore T200 Software Handbook (p. 210).

518 *Binding of R-synGAP to CaM-Sepharose*– Rosetta2(DE3) cells containing sr-synGAP or r-synGAP
519 were lysed in Lysis buffer as described in Walkup et al. (2015) except that the buffer contained 200 mM
520 NaCl, 0 or 5 mM CaCl_2 , and 0 or 10 mM EGTA. The resuspended cells were lysed by sonication with a
521 Digital Sonifier 450 Cell Disruptor (Branson, Danbury, CT) for two passes at 90 seconds/pass (15%
522 power, 1.0 second on, 1.5 seconds off), and insoluble material was removed by centrifugation at 16,000 \times
523 g for 40 min at 4 $^\circ$ C. Clarified cell lysate (1.7 ml) containing sr-synGAP or r-synGAP (~6 mg/ml total

524 protein) was incubated with end-over-end mixing for 60 min with 0.3 ml CaM-Sepharose 4B (GE
525 Healthcare Life Sciences, catalog no. 17-0529-01) or control Sepharose 4B (GE Healthcare Life Sciences,
526 catalog no. 17-0120-01). The resin was pipetted into a BioSpin column (Bio-Rad, catalog no. 732-6008)
527 and washed with 12 ml (40 column volumes) of Lysis/Wash Buffer. Bound protein was eluted with 1.2
528 ml (4 column volumes) of Lysis/Wash Buffer containing 100 mM EGTA. Eluted proteins (30 μ l aliquot)
529 were resolved by SDS-PAGE and transferred to a PVDF membrane which was probed with anti-synGAP
530 or BSA-free anti-TetraHis as described above.

531 *Measurement of Affinity of CaM for R-synGAP by SPR*– Direct binding of r-synGAP to Ca²⁺/CaM
532 immobilized on a chip was assayed on a Biacore T200 with a Series S Sensor Chip CM5. CaM (Enzo,
533 Farmingdale, NY, catalog no. BML-SE325-0001) was coupled to the chip by the amine coupling protocol
534 specified in the Biacore T200 Control Software, as described above. Purified, lyophilized CaM (250 μ g)
535 was resuspended in water and exchanged into Biacore Sodium Acetate, pH 4.0 Buffer (10 mM sodium
536 acetate, pH 4.0) with an Amicon Ultra-0.5 ml centrifugal filter with a 3 kDa molecular weight cutoff
537 (EMD Millipore, catalog no. UFC500396). CaM was further diluted to 0.5 nM in 10 mM Sodium
538 Acetate, pH 4.0, and injected into flow cells 2 and 4 until 50 RU of CaM were immobilized (~7 min at a
539 flow rate of 10 μ l/min). Flow cells 1 and 3 were left blank to be used as reference surfaces. Ethanolamine
540 (1 M, pH 8.5) was injected for 7 min at 10 μ l/min to block remaining active sites on all four flow cells. R-
541 synGAP (0 nM to 75 nM) in 1x HBS-EP+ running buffer supplemented with 10 mM CaCl₂, was injected
542 in triplicate at 25° C at 100 μ l/min for 75 sec over all four flow cells. Different concentrations of r-
543 synGAP were applied in randomized order. After injection ended, dissociation was monitored in each
544 flow cell for 500 sec. Regeneration of the sensor chip was performed by injecting 50 mM NaOH (GE
545 Healthcare Life Sciences, catalog no. BR-1003-58) at 100 μ l/min for 30 sec, waiting 180 sec for the
546 baseline to stabilize, then injecting a second pulse of NaOH, waiting 240 second for the baseline to
547 stabilize, and finally executing a “carry over control injection.” Sensorgrams were processed using the
548 Biacore T200 Evaluation Software, version 3.0, as described above. Resonance units of bound synGAP at
549 equilibrium were exported into Prism and plotted against the concentrations of r-synGAP. The data were

550 fit globally to a hyperbolic curve by nonlinear regression to determine equilibrium dissociation constants
551 (K_D).

552 *Determination of Affinity of Ca^{2+} /CaM for Sr- and R-synGAP by Equilibrium Binding to CaM-*

553 *Sepharose*– Purified sr-synGAP and r-synGAP were diluted to 1 to 500 nM in Binding/Wash Buffer (50
554 mM Tris, pH 7.5; 200 mM NaCl, 5 mM TCEP, 2 mM $CaCl_2$). Aliquots of diluted synGAP (300 μ l) were
555 incubated with end-over-end mixing for 60 minutes with 50 μ l of CaM-Sepharose 4B in a screw cap spin
556 column (Thermo Scientific, catalog no. 69705). Concentrations of sr- and r-synGAP were 20-3,000 fold
557 below the ligand binding capacity of the CaM-Sepharose resin. Unbound protein was removed by
558 centrifugation at 4,000 x g for 30 seconds. Beads were washed in Binding/Wash Buffer (250 μ l, 5
559 volumes), and bound protein was eluted with 50 μ l of 1x Laemmli buffer with 10% β -mercaptoethanol.
560 Eluted proteins were fractionated by SDS-PAGE and transferred to a PVDF membrane as described
561 above. Blots were probed with 1:1000 anti-synGAP or 1:1500 BSA-free anti-TetraHis anti-bodies and
562 quantified on a LI-COR Classic as described above. Integrated intensities reflecting the amount of bound
563 synGAP were determined with LI-COR software and plotted against the corresponding concentrations of
564 synGAP with Prism software. The data were fit to a hyperbolic curve by nonlinear regression to
565 determine the dissociation constant (K_D).

566 *Preparation of PSD fractions*– PSD fractions were prepared as previously described (Cho et al.,
567 1992) from six *wild-type* and six *SynGAP^{+/+}* mouse litter mates matched by age (7-12 weeks), and sex
568 (*wild-type*, 1 female, 5 males; *SynGAP^{+/+}*, 2 female, 4 male). The mice were killed by cervical dislocation
569 and forebrains were dissected and rinsed in Buffer A (0.32 M sucrose, 1 mM $NaHCO_3$, 1 mM $MgCl_2$, 0.5
570 mM $CaCl_2$, 0.1 mM PMSF, 1 mg/l leupeptin). Forebrains from each set of six mice were pooled and
571 homogenized with 12 up and down strokes at 900 rpm in 14 ml Buffer A. Homogenates were diluted to
572 35 ml in Buffer A and centrifuged at 1400 \times g for 10 min. The pellet was resuspended in 35 ml Buffer A,
573 homogenized (3 strokes), and centrifuged at 710 g for 10 min. Supernatants from the two centrifugations
574 were combined and centrifuged at 13,800 g for 10 min. The pellet was resuspended in 8 ml of Buffer B

575 (0.32 M sucrose, 1 mM NaH₂CO₃), homogenized with 6 strokes and layered onto a sucrose gradient (10
576 ml each of 0.85 M, 1.0 M, and 1.2 M sucrose in 1 mM NaH₂CO₃ buffer). The gradient was centrifuged
577 for 2 hours at 82,500 g in a swinging bucket rotor. The synaptosome-enriched layer at the interface of 1.0
578 and 1.2 M sucrose was collected, diluted to 15 ml with Solution B and added to an equal volume of
579 Buffer B containing 1% Triton. The mixture was stirred for 15 min at 4°C and centrifuged for 45 min at
580 36,800 g. The pellet containing the PSD-enriched, Triton-insoluble fraction was resuspended in 800-1000
581 µl of 40 mM Tris pH 8 with a 21 gauge needle and 1 ml syringe, and further solubilized by hand in a
582 teflon glass homogenizer. Samples were aliquoted and stored at -80° C.

583 *Quantification of Proteins in PSD Fractions*– PSD samples contained six pooled biological replicates
584 of each of the two genotypes. Equal amounts of protein from each PSD sample (5-15 µg) were dissolved
585 in SDS-PAGE sample buffer (33 mM Tris HCl, pH 6.8; 0.7% SDS, 10% glycerol, 2.5% β-
586 mercaptoethanol, and 0.003% bromophenol blue), heated at 90 °C for 5 min, fractionated on
587 polyacrylamide gels (8% or 10%), and electrically transferred to PVDF membranes in pre-cooled 25 mM
588 Tris, 150 mM glycine, 2% methanol at 250V for 2.5 hours at 4°C. Membranes were blocked with Odyssey
589 blocking buffer (LI-COR Biosciences) and then incubated in a primary antibody solution of 5% BSA in
590 TBS-T overnight at 4°C, as described above. Primary antibodies included mouse-anti-PSD-95
591 (ThermoFisher, catalog no. MA1-046 [clone 7E3-1B8], dilution 1:10,000), rabbit-anti-SynGAP (Pierce,
592 catalog no. PA1-046, dilution 1:3500), rabbit-anti-TARP (γ-2,3,4, and 8; EMD Millipore, catalog no.
593 Ab9876; dilution 1:300), rabbit-anti-LRRTM2 (Pierce, catalog no. PA521097; dilution 1:3000), mouse-
594 anti-neuroigin-1 (Sigma, catalog no. sab5201464; dilution 1:250), and rabbit-anti-neuroigin-2 (Synaptic
595 Systems, Germany, catalog no. 129202; dilution 1:1000). The membranes were then washed 3-times in
596 TBS-T. The membrane was incubated with secondary antibodies (Alexa Fluor 680-goat-anti-mouse IgG
597 (Life Technologies, catalog no. A21057; 1:10,000) or IRDye800-goat-anti-rabbit IgG (Rockland,
598 Limerick, PA, catalog no. 611-132-122; 1:10,000) for 45 minutes at room temperature in 5% nonfat milk
599 in TBS-T, then washed 3 times in TBS-T, then twice in TBS prior to scanning. For most experiments, each

600 blot contained 6 duplicate samples of PSD fractions from *wild-type* and the same number from *synGAP*^{+/+}
601 mice. Each blot was incubated with a mixture of two primary antibodies; mouse-anti-PSD-95 and the
602 antibody against neuroligin-1, neuroligin-2, TARPs, LRRTM2, or synGAP. Then the blots were incubated
603 with a mixture of the appropriate secondary antibodies. For measurement of neuroligin-1, both PSD-95
604 and neuroligin-1 were detected by the same goat anti-mouse secondary; the bands were physically
605 separated on the gel and were quantified independently. Bound antibodies were visualized in the
606 appropriate fluorescent channels with an Odyssey Classic Infrared Imaging System (LI-COR Biosciences,
607 Lincoln, Nebraska).

608 Before running samples for quantification, we determined empirically the amount of PSD sample that
609 would result in signals for each protein that were strong enough for measurement and not saturated. To
610 quantify the densities of the bands, each visual image was first set to high brightness in order to capture the
611 boundaries of the signals for each band. The images were then used as a template in LI-COR software to
612 draw rectangular regions of interest around protein bands, and around identically sized background regions
613 in the same lane. Background densities were subtracted from each protein signal. Two blots were excluded
614 because background density formed a gradient across the gel resulting in more variation in measurement
615 for one of the genotypes. The Digital data read by the LI-COR software is unchanged by the visualization
616 settings and is linear over several orders of magnitude. For each lane, the ratio of the integrated density of
617 each of the five proteins to the integrated density of PSD-95 was calculated. For three gels, one outlier
618 measurement (defined as greater than 2 times the standard deviation of the mean) was excluded from the
619 calculation. A few bands were also excluded from measurement when a bubble during the transfer
620 distorted and blurred the signal. The mean and standard error of the mean (S.E) of the ratios were
621 determined for *wild-type* and *synGAP*^{+/+} PSD fractions. The means were compared by t-tests performed
622 with Prism software as indicated in the legend of Fig. 9. For four of the proteins, the number of
623 measurements was sufficient to determine a significant difference between *wild-type* and *synGAP*^{+/+}. In the
624 case of neuroligin-1, the means were identical after 24 individual measurements of each sample.

625

626 **Acknowledgements**

627 This work was supported in part by grants from the Gordon and Betty Moore Foundation (Center for
628 Integrative Study of Cell Regulation), the Hicks Foundation for Alzheimer's Research, the Allen and
629 Lenabelle Davis Foundation, and from National Institutes of Health Grant MH095095 to MBK. WGW IV
630 was supported by the National Science Foundation Graduate Research Fellowship under Grant No.
631 2006019582, and the National Institutes of Health under Grant No. NIH/NRSA 5 T32 GM07616. The
632 Protein Expression Center is supported by the Beckman Institute.

633 **Conflict of interest:** The authors declare that they have no conflicts of interest concerning the contents of
634 this article.

635

1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

References

Abdiche YN, Malashock DS, Pons J. 2008. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. *Protein Sci* 17:1326-1335. doi: 10.1110/ps.035402.108

Araki Y, Zeng M, Zhang M, Haganir RL. 2015. Rapid dispersion of SynGAP from synaptic spines triggers AMPA receptor insertion and spine enlargement during LTP. *Neuron* 85:173-189. doi: 10.1016/j.neuron.2014.12.023

Barnett MW, Watson RF, Vitalis T, Porter K, Komiyama NH, Stoney PN, Gillingwater TH, Grant SG, Kind PC. 2006. Synaptic Ras GTPase activating protein regulates pattern formation in the trigeminal system of mice. *J Neurosci* 26:1355-1365. doi: 10.1523/JNEUROSCI.3164-05.2006

Baron MK, Boeckers TM, Vaida B, Faham S, Gingery M, Sawaya MR, Salyer D, Gundelfinger ED, Bowie JU. 2006. An architectural framework that may lie at the core of the postsynaptic density. *Science* 311:531-535. doi: 10.1126/science.1118995

Berryer MH, Hamdan FF, Klitten LL, Moller RS, Carmant L, Schwartzenruber J, Patry L, Dobrzeniecka S, Rochefort D, Neugnot-Cerioli M et al. 2013. Mutations in SYNGAP1 cause intellectual disability, autism, and a specific form of epilepsy by inducing haploinsufficiency. *Hum Mutat* 34:385-394. doi: 10.1002/humu.22248

25

26 Brenman JE, Chao DS, Gee SH, McGee AW, Craven SE, Santillano DR, Wu Z, Huang F, Xia H,
27 Peters MF et al. 1996. Interaction of nitric-oxide synthase with the postsynaptic density protein PSD-95
28 and alpha-1-syntrophin mediated by PDZ domains. *Cell* 84:757-767.

29

30 Chen H-J, Rojas-Soto M, Oguni A, Kennedy MB. 1998. A synaptic Ras-GTPase activating protein
31 (p135 SynGAP) inhibited by CaM Kinase II. *Neuron* 20:895-904.

32

33 Chen X, Vinade L, Leapman RD, Petersen JD, Nakagawa T, Phillips TM, Sheng M, Reese TS. 2005.
34 Mass of the postsynaptic density and enumeration of three key molecules. *Proc Natl Acad Sci U S A*
35 102:11551-11556. doi: 10.1073/pnas.0505359102

36

37 Cheng D, Hoogenraad CC, Rush J, Ramm E, Schlager MA, Duong DM, Xu P, Wijayawardana SR,
38 Hanfelt J, Nakagawa T et al. 2006. Relative and absolute quantification of postsynaptic density proteome
39 isolated from rat forebrain and cerebellum. *Mol Cell Proteomics* 5:1158-1170. doi: 10.1074/mcp.D500009-
40 MCP200

41

42 Cho K-O, Hunt CA, Kennedy MB. 1992. The rat brain postsynaptic density fraction contains a
43 homolog of the *Drosophila* discs-large tumor suppressor protein. *Neuron* 9:929-942.

44

45 Clement JP, Ozkan ED, Aceti M, Miller CA, Rumbaugh G. 2013. SYNGAP1 links the maturation rate
46 of excitatory synapses to the duration of critical-period synaptic plasticity. *J Neurosci* 33:10447-10452.
47 doi: 10.1523/JNEUROSCI.0765-13.2013

48

49 Cohen P, Klee CB. 1988. *Calmodulin*. Elsevier, Amsterdam, New York, N.Y.

50

51 de Wit J, Sylwestrak E, O'Sullivan ML, Otto S, Tiglio K, Savas JN, Yates JR, 3rd, Comoletti D,
52 Taylor P, Ghosh A. 2009. LRRTM2 interacts with Neurexin1 and regulates excitatory synapse formation.
53 *Neuron* 64:799-806. doi: 10.1016/j.neuron.2009.12.019

54

55 Dosemeci A, Makusky AJ, Jankowska-Stephens E, Yang X, Slotta DJ, Markey SP. 2007. Composition
56 of the synaptic PSD-95 complex. *Mol Cell Proteomics* 6:1749-1760. doi: 10.1074/mcp.M700040-MCP200

57

58 El-Husseini AE, Craven SE, Chetkovich DM, Firestein BL, Schnell E, Aoki C, Brecht DS. 2000. Dual
59 Palmitoylation of PSD-95 Mediates Its Vesiculotubular Sorting, Postsynaptic Targeting, and Ion Channel
60 Clustering. *J Cell Biol* 148:159-172.

61

62 Hamdan FF, Daoud H, Piton A, Gauthier J, Dobrzyniecka S, Krebs MO, Joobor R, Lacaille JC,
63 Nadeau A, Milunsky JM et al. 2011. De novo SYNGAP1 mutations in nonsyndromic intellectual disability
64 and autism. *Biol Psychiatry* 69:898-901. doi: 10.1016/j.biopsych.2010.11.015

65

66 Hamdan FF, Gauthier J, Spiegelman D, Noreau A, Yang Y, Pellerin S, Dobrzeniecka S, Cote M,
67 Perreau-Linck E, Carmant L et al. 2009. Mutations in SYNGAP1 in autosomal nonsyndromic mental
68 retardation. *N Engl J Med* 360:599-605. doi: 10.1056/NEJMoa0805392

69

70 Hayashi Y, Shi SH, Esteban JA, Piccini A, Poncer JC, Malinow R. 2000. Driving AMPA receptors
71 into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction. *Science*
72 287:2262-2267.

73

74 He L, Hou Z, Qi RZ. 2008. Calmodulin binding and Cdk5 phosphorylation of p35 regulate its effect on
75 microtubules. *J Biol Chem* 283:13252-13260. doi: 10.1074/jbc.M706937200

76

77 Henley JM, Wilkinson KA. 2016. Synaptic AMPA receptor composition in development, plasticity
78 and disease. *Nat Rev Neurosci*. 10.1038/nrn.2016.37

79

80 Hubbard MJ, Klee CB. 1987. Calmodulin binding by calcineurin. Ligand-induced renaturation of
81 protein immobilized on nitrocellulose. *J Biol Chem* 262:15062-15070.

82

83 Hudmon A, Schulman H. 2002. Neuronal Ca²⁺/calmodulin-dependent protein kinase II: The role of
84 structure and autoregulation in cellular function. *Annu Rev Biochem* 71:473-510. doi:

85 10.1146/annurev.biochem.71.110601.135410

86

87 Irie M, Hata Y, Takeuchi M, Ichtchenko A, Toyoda A, Hirao K, Takai Y, Rosahl TW, Sudhof TC.

88 1997. Binding of neuroligins to PSD-95. *Science* 277:1511-1515.

89

90 Kennedy MB. 2000. Signal-processing machines at the postsynaptic density. *Science* 290:750-754.

91 doi: [10.1126/science.290.5492.750](https://doi.org/10.1126/science.290.5492.750)

92

93 Kennedy MB. 2013. Synaptic signaling in learning and memory. *Cold Spring Harb Perspect*

94 *Biol*:a016824. doi: [10.1101/cshperspect.a016824](https://doi.org/10.1101/cshperspect.a016824)

95

96 Kim JH, Lee HK, Takamiya K, Huganir RL. 2003. The role of synaptic GTPase-activating protein in

97 neuronal development and synaptic plasticity. *J Neurosci* 23:1119-1124.

98

99 Kim JH, Liao D, Lau L-F, Huganir RL. 1998. SynGAP: a synaptic RasGAP that associates with the

100 PSD-95/SAP90 protein family. *Neuron* 20:683-691.

101

102 Komiyama NH, Watabe AM, Carlisle HJ, Porter K, Charlesworth P, Monti J, Strathdee DJ, O'Carroll

103 CM, Martin SJ, Morris RG et al. 2002. SynGAP regulates ERK/MAPK signaling, synaptic plasticity, and

104 learning in the complex with postsynaptic density 95 and NMDA receptor. *J Neurosci* 22:9721-9732.

105

106 Kornau H-C, Schenker LT, Kennedy MB, Seeburg PH. 1995. Domain interaction between NMDA

107 receptor subunits and the postsynaptic density protein PSD-95. *Science* 269:1737-1740. doi:

108 [10.1126/science.7569905](https://doi.org/10.1126/science.7569905)

109

110 Kornau H-C, Seeburg PH, Kennedy MB. 1997. Interaction of ion channels and receptors with PDZ
111 domain proteins. *Curr Opin Neurobiol* 7:368-373.

112

113 Kurakin A, Swistowski A, Wu SC, Bredesen DE. 2007. The PDZ domain as a complex adaptive
114 system. *PLoS One* 2:e953. doi: 10.1371/journal.pone.0000953

115

116 Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC et al.
117 2006. Engineered antibody Fc variants with enhanced effector function. *Proc Natl Acad Sci U S A*
118 103:4005-4010. doi: 10.1073/pnas.0508123103

119

120 Levinson JN, Chery N, Huang K, Wong TP, Gerrow K, Kang R, Prange O, Wang YT, El-Husseini A.
121 2005. Neuroligins mediate excitatory and inhibitory synapse formation: involvement of PSD-95 and
122 neurexin-1beta in neuroligin-induced synaptic specificity. *J Biol Chem* 280:17312-17319. doi:
123 10.1074/jbc.M413812200

124

125 Levinson JN, El-Husseini A. 2005. Building excitatory and inhibitory synapses: balancing neuroligin
126 partnerships. *Neuron* 48:171-174. doi: 10.1016/j.neuron.2005.09.017

127

128 Markram H, Roth A, Helmchen F. 1998. Competitive calcium binding: implications for dendritic
129 calcium signaling. *J Comput Neurosci* 5:331-348.

130

131 McMahon AC, Barnett MW, O'Leary TS, Stoney PN, Collins MO, Papadia S, Choudhary JS,
132 Komiyama NH, Grant SG, Hardingham GE et al. 2012. SynGAP isoforms exert opposing effects on
133 synaptic strength. *Nat Commun* 3:900. doi: 10.1038/ncomms1900

134

135 Meyer T, Hanson PI, Stryer L, Schulman H. 1992. Calmodulin trapping by calcium-calmodulin
136 dependent protein kinase. *Science* 256:1199-1202.

137

138 Miller SG, Kennedy MB. 1985. Distinct forebrain and cerebellar isozymes of type II Ca²⁺/calmodulin-
139 dependent protein kinase associate differently with the postsynaptic density fraction. *J Biol Chem*
140 260:9039-9046.

141

142 Mruk K, Farley BM, Ritacco AW, Kobertz WR. 2014. Calmodulation meta-analysis: predicting
143 calmodulin binding via canonical motif clustering. *J Gen Physiol* 144:105-114. doi:
144 10.1085/jgp.201311140

145

146 Murphy JA, Jensen ON, Walikonis RS. 2006. BRAG1, a Sec7 domain-containing protein, is a
147 component of the postsynaptic density of excitatory synapses. *Brain Res* 1120:35-45. doi:
148 10.1016/j.brainres.2006.08.096

149

150 Nieba L, Krebber A, Pluckthun A. 1996. Competition BIAcore for measuring true affinities: large
151 differences from values determined from binding kinetics. *Anal Biochem* 234:155-165. doi:
152 10.1006/abio.1996.0067

153

154 Opazo P, Choquet D. 2011. A three-step model for the synaptic recruitment of AMPA receptors. in
155 *Mol Cell Neurosci*, pp. 1-8.

156

157 Opazo P, Labrecque S, Tigaret CM, Frouin A, Wiseman PW, De Koninck P, Choquet D. 2010.
158 CaMKII triggers the diffusional trapping of surface AMPARs through phosphorylation of stargazin. in
159 *Neuron*, pp. 239-252.

160

161 Opazo P, Sainlos M, Choquet D. 2012. Regulation of AMPA receptor surface diffusion by PSD-95
162 slots. *Curr Opin Neurobiol* 22:453-460. doi: 10.1016/j.conb.2011.10.010

163

164 Pepke S, Kinzer-Ursem T, Mihalas S, Kennedy MB. 2010. A dynamic model of interactions of Ca²⁺,
165 calmodulin, and catalytic subunits of Ca²⁺/calmodulin-dependent protein kinase II. in *PLoS Comput Biol*,
166 p. e1000675. Public Library of Science.

167

168 Rumbaugh G, Adams JP, Kim JH, Huganir RL. 2006. SynGAP regulates synaptic strength and
169 mitogen-activated protein kinases in cultured neurons. *Proc Natl Acad Sci U S A* 103:4344-4351. doi:
170 10.1073/pnas.0600084103

171

172 Sakagami H, Sanda M, Fukaya M, Miyazaki T, Sukegawa J, Yanagisawa T, Suzuki T, Fukunaga K,
173 Watanabe M, Kondo H. 2008. IQ-ArfGEF/BRAG1 is a guanine nucleotide exchange factor for Arf6 that
174 interacts with PSD-95 at postsynaptic density of excitatory synapses. *Neurosci Res* 60:199-212. doi:
175 10.1016/j.neures.2007.10.013

176

177 Schapitz IU, Behrend B, Pechmann Y, Lappe-Siefke C, Kneussel SJ, Wallace KE, Stempel AV, Buck
178 F, Grant SG, Schweizer M et al. 2010. Neuroligin 1 is dynamically exchanged at postsynaptic sites. *J*
179 *Neurosci* 30:12733-12744. doi: 10.1523/JNEUROSCI.0896-10.2010

180

181 Sheng M, Hoogenraad CC. 2007. The postsynaptic architecture of excitatory synapses: a more
182 quantitative view. *Annu Rev Biochem* 76:823-847. doi: 10.1146/annurev.biochem.76.060805.160029

183

184 Sheng M, Kim E. 2011. The postsynaptic organization of synapses. in *Cold Spring Harb Perspect*
185 *Biol*, pp. a005678, doi: 005610.001101/cshperspect.a005678.

186

187 Shi S, Hayashi Y, Esteban JA, Malinow R. 2001. Subunit-specific rules governing AMPA receptor
188 trafficking to synapses in hippocampal pyramidal neurons. *Cell* 105:331-343.

189

190 Siddiqui TJ, Pancaroglu R, Kang Y, Rooyackers A, Craig AM. 2010. LRRTMs and neuroligins bind
191 neurexins with a differential code to cooperate in glutamate synapse development. *J Neurosci* 30:7495-
192 7506. doi: 10.1523/JNEUROSCI.0470-10.2010

193

194 Sjöström PJ, Nelson SB. 2002. Spike timing, calcium signals and synaptic plasticity. *Curr Opin*
195 *Neurobiol* 12:305-314.

196

197 Steiner P, Higley MJ, Xu W, Czervionke BL, Malenka RC, Sabatini BL. 2008. Destabilization of the
198 postsynaptic density by PSD-95 serine 73 phosphorylation inhibits spine growth and synaptic plasticity.
199 *Neuron* 60:788-802. doi: 10.1016/j.neuron.2008.10.014

200

201 Sturgill JF, Steiner P, Czervionke BL, Sabatini BL. 2009. Distinct domains within PSD-95 mediate
202 synaptic incorporation, stabilization, and activity-dependent trafficking. *J Neurosci* 29:12845-12854. doi:
203 10.1523/JNEUROSCI.1841-09.2009

204

205 Sudhof TC. 2008. Neuroligins and neurexins link synaptic function to cognitive disease. *Nature*
206 455:903-911. doi: 10.1038/nature07456

207

208 Sugiyama Y, Kawabata I, Sobue K, Okabe S. 2005. Determination of absolute protein numbers in
209 single synapses by a GFP-based calibration technique. *Nat Methods* 2:677-684. doi: 10.1038/nmeth783

210

211 Tomita S, Stein V, Stocker TJ, Nicoll RA, Brecht DS. 2005. Bidirectional synaptic plasticity regulated
212 by phosphorylation of stargazin-like TARPs. *Neuron* 45:269-277. doi: 10.1016/j.neuron.2005.01.009

213

214 Varoqueaux F, Jamain S, Brose N. 2004. Neuroligin 2 is exclusively localized to inhibitory synapses.
215 *Eur J Cell Biol* 83:449-456. 10.1078/0171-9335-00410

216

217 Vazquez LE, Chen HJ, Sokolova I, Knuesel I, Kennedy MB. 2004. SynGAP regulates spine formation.
218 *J Neurosci* 24:8862-8872. doi: 10.1523/JNEUROSCI.3213-04.2004

219

220 Walkup IV WG, Kennedy MB. 2014. PDZ affinity chromatography: a general method for affinity
221 purification of proteins based on PDZ domains and their ligands. *Protein Expr Purif* 98:46-62. doi:
222 10.1016/j.pep.2014.02.015

223

224 Walkup IV WG, Kennedy MB. 2015. Protein purification using PDZ affinity chromatography. *Curr*
225 *Protoc Protein Sci* 80:9.10.11-19.10.37. doi: 10.1002/0471140864.ps0910s80

226


227 Walkup IV WG, Washburn L, Sweredoski MJ, Carlisle HJ, Graham RL, Hess S, Kennedy MB. 2015.
228 Phosphorylation of synaptic GTPase-activating protein (synGAP) by Ca²⁺/calmodulin-dependent protein
229 kinase II (CaMKII) and cyclin-dependent kinase 5 (CDK5) alters the ratio of its GAP activity toward ras
230 and rap GTPases. *J Biol Chem* 290:4908-4927. doi: 10.1074/jbc.M114.614420

231

232 Yang Y, Tao-Cheng JH, Bayer KU, Reese TS, Dosemeci A. 2013. CaMKII-mediated phosphorylation
233 regulates distributions of SynGAP-alpha1 and -alpha2 at the postsynaptic density. *PLoS One* 8:e71795.
234 doi: 10.1371/journal.pone.0071795

235

236




2

3

4 **FIGURE 1. Phosphorylation by CaMKII regulates association of r-synGAP with PDZ domains of PSD-**
5 **95.** *A*, Domain diagrams of synGAP (Walkup IV et al., 2015) and PSD-95 (Cho et al., 1992). The
6 boundaries of r-synGAP and sr-synGAP are indicated, as are the locations of the major sites
7 phosphorylated by CaMKII, most of which are in the “disordered domain.” Numbering is based on rat
8 isoform synGAP A1- α 1. The 5 residue PDZ ligand is located at the C-terminus. The five major domains
9 of PSD-95, including the approximate relationships of its three N-terminal PDZ domains are indicated.
10 *B*, Association of r-synGAP with PDZ domains of PSD-95 before and after phosphorylation by CaMKII.
11 R-synGAP was incubated in a phosphorylation mix for 10 min with either 0 CaMKII and 0 Ca^{2+} /CaM
12 (control) or 10 nM CaMKII and 0.7 mM CaCl_2 /3.4 μM CaM (+ CaMKII) before binding to PDZ domain
13 resins for 60 min at 25° C, as described under Materials and Methods. For comparison of binding of
14 control to phosphorylated synGAP: PDZ1, $p < 0.0001$; PDZ2, $p = 0.0001$; PDZ3, $p < 0.0001$; PDZ12, $p =$
15 0.002 ; PDZ123, $p < 0.0001$ *C*, Both Ca^{2+} /CaM and CaMKII are required in the phosphorylation reaction to
16 reduce binding of synGAP to PDZ123 resin. R-synGAP was incubated in the phosphorylation reaction
17 without Ca^{2+} /CaM or CaMKII (Control), with CaMKII alone, or with both before binding to PDZ resin.
18 For comparison of Control to phosphorylation: + CaMKII, $p = 0.2$; + Ca^{2+} /CaM, +CaMKII, $p < 0.0001$.
19 The final bar shows that phosphorylation of the PDZ123 domain resin itself doesn’t alter binding of r-
20 synGAP. PDZ123 domain affinity resin was phosphorylated for 60 min in the presence of CaMKII and
21 0.7 mM CaCl_2 /3.4 μM CaM before incubation with control r-synGAP (500 nM) for 60 min at 25° C. For
22 comparison to Control, $p = 0.7$. *D*, Stoichiometry of phosphorylation of r-synGAP by CaMKII. R-
23 synGAP (725 nM) was phosphorylated in the presence of CaMKII (10 nM), as described under
24 “Materials and Methods.” At the indicated times, reactions were quenched by addition of 3x Laemmli
25 sample buffer. Radiolabeled r-synGAP was isolated by SDS-PAGE and quantified as described under
26 “Materials and Methods.” *E*, Change in affinity of r-synGAP for PDZ123 after phosphorylation by
27 CaMKII for times corresponding to those measured in *D*. R-synGAP was phosphorylated for 0.5 to 10
28 min as described in *D* before incubation with PDZ123 domain affinity resin for 60 min as described under
29 “Materials and Methods.” Control (-CaMKII, - Ca^{2+} /CaM) is r-synGAP incubated in the phosphorylation

30 reaction in the absence of CaMKII and Ca²⁺/CaM. For Caomparison of Control to phosphorylation for
31 0.5, 1, 2, 5, or 10 min, p <0.0001. Pairwise comparisons among all phosphorylation conditions showed
32 no significant differences (p from 0.4 to 1). Data shown in *B-E* are plotted as mean ± S.E. (n=4). For *B*,
33 *C*, and *E*, the statistical significance of differences in binding to PDZ domain resin relative to
34 unphosphorylated r-synGAP control (-Ca²⁺/CaM) was determined by ordinary one way ANOVA
35 (uncorrected Fisher's LSD). **, p<0.01; ***, p<0.001; ****, p<0.0001.


36



37

38 **FIGURE 1 -figure supplement 1. Purification of recombinant PDZ domains of PSD-95.** PDZ domains
39 of PSD-95 were expressed in *E. coli* individually or combined in a single peptide, as indicated, and
40 purified as described under “Materials and Methods.” Proteins in the starting soluble fraction (S) and
41 eluted from PDZ ligand affinity columns (E) were fractionated on 12% (PDZ1, PDZ2, PDZ3, PDZ12) or
42 4-12% gradient (PDZ123) SDS-polyacrylamide gels and stained as described under “Materials and
43 Methods.”

44



45

46 **FIGURE 2.** Measurement of affinity of r-synGAP for PDZ1 of PSD-95 by the "competition in solution"

47 method. *A*, Biacore sensorgrams showing the calibration curves (grey lines) for binding of 0-50 nM r-

48 synGAP and the measurement of free r-synGAP (samples; black lines) in mixtures containing 25 nM r-

49 synGAP and 0-10 μ M PDZ1 domain. Free r-synGAP was detected by binding to PDZ1 domains


50 immobilized on a Biacore chip as described under Materials and Methods. *B*, A standard calibration curve

51 was constructed by plotting the maximum calibrated resonance responses (marked by arrow in *A*) against

52 the corresponding concentrations of r-synGAP (large grey dots). The maximum resonance responses for

53 each sample mixture were plotted on the standard curve to determine the free r-synGAP concentrations in

54 each mixture (black dots). *C*, Plot of free r-synGAP concentrations determined in *B* against the log of
55 PDZ domain concentrations (black circles). The data were fit to the binding equation shown in Materials
56 and Methods with the use of Graphpad Prism software. A K_D value (Table 1) was calculated from the
57 equation as described under Materials and Methods.
58



59

60 **FIGURE 3.** Affinities and apparent affinities of r-synGAP for PDZ2, PDZ3, PDZ12 and PDZ123

61 domains of PSD-95 determined by the “competition in solution” method. The concentrations of free r-

62 synGAP in sample mixtures containing each of the indicated PDZ domains were measured as described in


63 Fig. 3A and B, and under Materials and Methods. The values (black dots) were plotted against the log of

64 the PDZ domain concentration and fit to a binding curve as described in Fig. 3C. Representative

65 experiment for A, PDZ2; B, PDZ3; C, PDZ12; and D, PDZ123. The calculated K_D and K_{Dapp} values from

66 all experiments are listed in Table 1.

67



68

69 **FIGURE 4.** Effect of phosphorylation by CaMKII on association of PDZ123 domains with phospho-

70 deficient and phospho-mimetic mutants of r-synGAP. Wild-type and mutant r-synGAP were incubated

71 with phosphorylation mixtures for 10 min without (Control) or for 0.5 or 10 min with 10 nM CaMKII, 0.7

72 mM CaCl₂/3.4 μM CaM (CaMKII) then incubated with PDZ123 affinity resin for 60 min at 25° C, as

73 described under “Materials and Methods.” *A*, Binding of r-synGAP and r-synGAP mutants S1123A,

74 S1123D, and S1099A/S1123A are represented by the indicated shades of grey bars. For comparison of

75 WT to mutants after 0.5 min phosphorylation: S1123A, $p = 0.001$; S1123D, $p = 0.04$; S1093A/S1123A, p


76 $= 0.005$. For comparison of WT to mutants after 10 min phosphorylation: S1123A, $p = 0.625$; S1123D, p

77 $= 0.437$; S1093A/S1123A, $p = 0.867$. For comparison of WT and each mutant after 0.5 and 10 min

78 phosphorylation: WT, $p = 0.07$; S1123A, $p = 0.04$; S1123D, $p = 0.30$; S1093A/S1123A, $p = 0.366$. *B*,

79 Binding of r-synGAP and r-synGAP mutants S1283A and S1283D are represented by the indicated
80 shades of grey bars. For comparison of WT to mutants before phosphorylation: S1283A, $p = 0.2$;
81 S1283D, $p < 0.0001$; For comparison of S1283A to S1283D, $p = 0.0009$. For comparison of WT to
82 mutants after 0.5 min phosphorylation: S1283A, $p = 0.0001$; S1283D, $p = 0.002$. For comparison of WT
83 and mutants after 0.5 and 10 min phosphorylation: WT, $p = 0.2$, S1283A, $p = 0.001$; S1283D, $p = 0.007$.
84 Data are mean \pm S.E. ($n=4$). The statistical significance of differences in PDZ domain binding among
85 wild-type and mutant samples was determined by ordinary one way ANOVA (uncorrected Fisher's LSD).
86 *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.005$; ****, $p < 0.0001$.


87



88

89

90 **FIGURE 5.** Apparent affinities of phosphorylated r-synGAP and r-synGAP-S1283D for PDZ123
91 determined by the “competition in solution” method. Representative plots of the concentrations of (A)
92 free phospho-r-synGAP phosphorylated as described for PDZ Binding Assays under Materials and
93 Methods, and (B) r-synGAP-S1283D, measured in sample mixtures containing PDZ123 as described in
94 Fig. 3A and B, and under Materials and Methods. The values (black dots) were plotted against the log of
95 the PDZ123 concentration in the mixture and fit to a binding curve as described in Fig. 3C. The calculated
96 K_{Dapp} values are listed in Table 1.




97


98 **FIGURE 6.** Effect of Ca²⁺/CaM on stoichiometry of phosphorylation of r-synGAP and Histone H1 by
 99 CDK5. Stoichiometry of phosphorylation of r-synGAP (A-B) and Histone H1 (C-D) by CDK5/p35 or
 100 CDK5/p25. R-synGAP (286 nM) or Histone H1 (4.3 μM) were incubated with CDK5/p35 or CDK5/p25
 101 as described under “Materials and Methods” in the presence or absence of 0.7 mM CaCl₂ or 3.4 μM CaM,
 102 as indicated in each panel. Reactions were quenched at the indicated times by addition of 3x Laemmli
 103 sample buffer and radiolabeled r-synGAP and Histone H1 were quantified as described under Materials
 104 and Methods. For comparison of phosphorylation in the presence and absence of Ca²⁺/CaM: A) 10 min, p
 105 = 0.01; 30 min, p < 0.0001; 60 min, p < 0.0001. B) 10 min, p = 0.001; 30 min, p < 0.0001, 60 min, p <

106 0.0001. C) 0.5 min, $p = 0.5$; 1 min, $p = 0.9$; 2 min, $p = 0.4$. D) 0.5 min, $p = 0.5$; 1 min, $p = 0.3$; 2 min, $p =$
107 0.2. Data are plotted as mean \pm S.E. ($n = 4-7$). The statistical significance of differences in
108 phosphorylation in the presence of Ca^{2+} and CaM were determined by ordinary one way ANOVA
109 (uncorrected Fisher's LSD). **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.

110



111
 112 **FIGURE 6 - figure supplement 1. R-synGAP binds to CaM affinity resin.** Clarified *E. coli* lysate (Load)
 113 containing r-synGAP was incubated with CaM-Sepharose 4B or control Sepharose 4B resin in the
 114 presence of 0 or 5 mM CaCl₂ and 0 or 10 mM EGTA, as described under “Materials and Methods.”
 115 After washing, bound protein was eluted from the resin with 100 mM EGTA (Eluate), fractionated by
 116 SDS-PAGE, and visualized by staining with Gel Code Blue (Total Protein) or transferred to a PVDF
 117 membrane. R-synGAP was detected on the immunoblots with anti-synGAP or anti-TetraHis antibodies,
 118 as described under “Materials and Methods.” In the absence of exogenous calcium, r-synGAP bound
 119 weakly to the CaM-Sepharose, but not to control Sepharose beads. When 5 mM Ca²⁺ was included in the
 120 binding and wash buffers its binding to CaM-Sepharose increased, while addition of 10 mM EGTA to the
 121 buffers nearly abolished binding.
 122



123

124

125 **Figure 6 - figure supplement 2.** Effect of binding of Ca²⁺/CaM on GAP activity of r-synGAP. The GAP

126 activity of r-synGAP (250 nM) for the indicated GTP-binding protein was assayed as described in

127 Walkup et al. (2015) except that 1 mM Ca²⁺, 3.4 μM CaM, or both were added to the GAP assay as

128 indicated. *A*, HRas GAP activity; *B*, Rap1 GAP activity; and *C*. Rap2 GAP activity. Data are mean ± S.E.

129 The statistical significance of differences between activity in the presence of r-synGAP in the absence of


130 Ca²⁺ or CaM (second column) and all other conditions was determined by ordinary one way ANOVA

131 (uncorrected Fisher's LSD). ****, p<0.0001. For comparison of GAP activities in the absence and

132 presence of synGAP: HRas, Rap1 or Rap2, p < 0.0001. For comparisons of reactions containing

133 synGAP: HRas, p ranged from 0.3 to 0.9; Rap1, p ranged from 0.5 to 0.7; Rap2, p ranged from 0.5 to 0.6.

134



135

136

137

138

139

140

141

142

143


144

145

146

FIGURE 7. Affinity of r-synGAP for Ca²⁺/CaM determined by equilibrium analysis. (A-B) The affinity of r-synGAP for Ca²⁺/CaM was measured by SPR with CaM immobilized on the chip and r-synGAP injected at 0-50 nM onto the chip surface as described under Materials and Methods. A, Sensorgrams with the blank and reference flow cell readings subtracted show the response upon injection of r-synGAP onto the chip surface (0-75 seconds) and its dissociation from the chip surface (75-150 seconds). B, RUs at equilibrium (marked by arrow in A) were plotted against the corresponding concentrations of r-synGAP and fitted to a hyperbolic curve. A K_D of 9 ± 1 nM was calculated as described under Materials and Methods. C and D, The affinities of r-synGAP and sr-synGAP (0-500 nM) for Ca²⁺/CaM were measured by incubation with CaM-Sepharose resin as described under Materials and Methods. Integrated intensities of bound r- and sr-synGAP were measured from immunoblots as described under Materials and Methods and plotted versus the corresponding concentrations incubated with resin.

147 Integrated intensities from Western blots were linear over the range of r- and sr-synGAP concentrations
148 used in the assays *C*, r-synGAP; and *D*, sr-synGAP. Data in *C* and *D* are plotted as mean \pm S.E. (n = 3).
149



150

151 **FIGURE 8.** Effect of Ca²⁺/CaM binding on association of r-synGAP with PDZ domains of PSD-95.

152 *A*, Association of control and Ca²⁺/CaM bound r-synGAP with PDZ domains of PSD-95. R-synGAP (500

153 nM) without (Control) or with (+ CaM) 0.7 mM CaCl₂/3.4 μM CaM was incubated with PDZ domain

154 resins (PDZ1, PDZ2, PDZ3, PDZ12, and PDZ123) for 60 min at 25° C and bound synGAP was measured

155 as described under Materials and Methods. For comparison of control to +Ca²⁺/CaM, PDZ1, p = 0.09;

156 PDZ2, p = 0.2; PDZ3, p = 0.003 (d = 1.9); PDZ12, P = 0.7; PDZ123, p = 0.0001 (d = 2.6). *B*, Effects of

157 bound Ca²⁺/CaM and phosphorylation by CaMKII on association of r-synGAP with PDZ123 domain are

158 not additive. The association of synGAP with PDZ123 domain resin was measured as in *A*, under four

159 different conditions: (Control), unphosphorylated r-synGAP alone; (plus CaM), Ca²⁺/CaM present in

160 excess of synGAP during the incubation with resin; (plus CaMKII), r-synGAP is prephosphorylated with


161 CaMKII as described under Materials and Methods, then Ca²⁺ is chelated with EGTA during the

162 incubation with resin; and (plus CaM and CaMKII), r-synGAP is prephosphorylated by CaMKII and

163 Ca²⁺/CaM is present in excess during incubation with resin. For comparison to Control: plus CaM, p

164 <0.0001; plus CaMKII, $p < 0.0001$; plus CaM and CaMKII, $p < 0.0001$. For comparison of “plus CaMKII”
165 and “plus CaM and CaMKII” samples, $p = 0.06$. Data are plotted as mean \pm S.E. ($n=4$). The statistical
166 significance of differences in PDZ domain binding relative to Control was determined by ordinary one way
167 ANOVA (uncorrected Fisher’s LSD). **, $p < 0.01$; ****, $p < 0.0001$.

168




169

170 **Figure 9.** Altered composition of the postsynaptic density in mice with heterozygous deletion of
 171 synGAP. Ratios of amounts of the indicated proteins to PSD-95 were measured as described in Materials
 172 and Methods and are reported as mean \pm S.E. For all blots except those for neuroligin-1, PSD-95 was
 173 detected with a secondary Ab labelled with AlexaFluor680 and the binding protein was detected with
 174 secondary Ab labelled with IRDye 800. On the neuroligin-1 blot, both PSD-95 and neuroligin-1 were
 175 detected with AlexaFluor680; the two bands were well-separated in each lane. Representative sets of

176 visualized bands for *wild-type* (WT) and *synGAP*^{+/+} (HET) from the same blot are shown below the graphs.
177 *A*, SynGAP to PSD-95 ratio. Data were collected for 22 lanes from two blots containing 5 μg total PSD
178 fraction per lane. One blot contained six lanes WT and six lanes HET samples, the other contained five
179 lanes of each. The mean ratio of synGAP to PSD-95 was 0.234 ± 0.012 for WT (n = 11) and 0.179 ± 0.005
180 (n = 11) for HET. Means were compared by unpaired, one-tailed t-test with Welch correction, p = 0.0007,
181 d = 1.75. *B*, TARP γ -2,3,4,8 to PSD-95 ratio. Data were collected for 24 lanes from two blots containing
182 10 μg total PSD fraction per lane. Each blot contained six lanes WT and six lanes HET samples. Densities
183 of all four TARPs were pooled. The mean ratio of TARPs to PSD-95 was 0.066 ± 0.003 (n = 12) for WT
184 and 0.075 ± 0.003 (n = 12) for HET. Means were compared by unpaired, one-tailed t-test with equal
185 variance, p = 0.017, d = 0.93. *C*, LRRTM2 to PSD-95 ratio. Data were collected for 36 lanes from three
186 blots containing six WT and six HET samples, alternating 5 and 10 μg (3 each). The mean ratio of
187 LRRTM2 to PSD-95 was 0.051 ± 0.003 for WT (n = 17) and 0.059 ± 0.003 for HET (n = 17). Means were
188 compared by paired, one-tailed t-test, p=0.0035, d = 0.66. *D*, Neuroligin-1 to PSD-95 ratio. Data were
189 collected for 47 lanes from four blots two of which contained 5 μg and two 10 μg total PSD fraction per
190 sample. Each blot contained six lanes WT and six lanes HET samples. The mean ratio of neuroligin-1 to
191 PSD-95 was 0.114 ± 0.005 (n = 24) for WT and 0.115 ± 0.004 (n = 23) for HET. Means were compared
192 by unpaired one-tailed t-test, p = 0.413, d = 0.07. *E*, Neuroligin-2 to PSD-95 ratio. Data were collected for
193 44 lanes from four blots containing 10 μg total PSD fraction per lane. Each blot contained six lanes WT
194 and six lanes HET samples. The mean ratio of neuroligin-2 to PSD-95 was 0.071 ± 0.002 (n = 20) for WT
195 and 0.078 ± 0.003 (n = 24) for HET. Means were compared by unpaired, one-tailed t-test with Welch
196 correction, p= 0.019, d = 0.64. *, p<0.05; **, p<0.01; ***, p<0.001

197



198

199 **FIGURE 10.** Cartoon model of rearrangement of PSD after phosphorylation of synGAP by CaMKII.

200 *A*, Unphosphorylated synGAP binds to PDZ1, PDZ2 or PDZ3 of PSD-95, occupying as many as ~30%
201 of its PDZ domains. The PDZ domains of PSD-95 are shown in blue and their numbers are indicated on
202 the left pair of PSD-95 molecules. AMPARs that have been inserted into the extrasynaptic membrane by
203 exocytosis associate with TARPs and with LRRTMs, both of which can bind to PDZ1 and PDZ2 of PSD-
204 95. Neuroligin-1 (NLG1) binds to PDZ3 of PSD-95. LRRTMs and NLG1 also bind across the synaptic
205 cleft to presynaptic neurexins. *B*, Calcium flux through NMDARs activates CaMKII leading to

206 phosphorylation of synGAP on sites in the regulatory domain. The affinity of synGAP for the PDZ
207 domains decreases, allowing TARPs, LRRTMs, and NLG-2 to displace synGAP by binding to the PDZ
208 domains. The shift in affinity of synGAP creates “slots” that can be occupied by AMPAR complexes, or
209 by neuroligin-2, leading to strengthening of the synapse.

210

211 **TABLE 1.** Affinities of R-synGAP for PDZ Domains of PSD-95

212 Dissociation constants (K_D or K_{Dapp}) for the interactions of synGAP with PDZ domains of PSD-95
 213 were determined by the Biacore/SPR “competition in solution” method as described under “Materials and
 214 Methods.” In one experiment, the K_D for PDZ3 was determined by conventional SPR as described under
 215 “Materials and Methods.” Goodness of Fit refers to the fit of the data shown in Figs. 2, 3, and 5 to the
 216 equation relating $\text{synGAP}_{\text{free}}$ to PDZ domain concentration described under “Materials and Methods.”
 217 Data are expressed as mean \pm S.E.

218

PDZ Domain from PSD-95	No. of Experiments	Dissociation Constant (K_D) for Binding r-synGAP (nM)	Goodness of Fit (R^2)
PDZ1	3	220 ± 30	0.908 - 0.947
PDZ2	2	1500 ± 100	0.967, 0.969
PDZ3	2	620 ± 70	0.951, 0.9624
PDZ3	1	730 ± 50 (by conventional SPR)	N.A.
		Apparent Dissociation Constant (K_{Dapp}) for Binding to R-synGAP (nM)	
PDZ12	4	350 ± 40	0.931 - 0.987
PDZ123	6	4.7 ± 0.6	0.957 - 0.985
PDZ123	3	(CaMKII Phosphorylated r-synGAP) 46 ± 10	0.810 - 0.880
PDZ123	2	(S1283D r-synGAP) 16 ± 3	0.953, 0.954

219